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ABSTRACT 
 A monolayer differs significantly from the multicellular nature and three-
dimensional growth of a tumor. Tumors are often modeled with a multicellular aggregate 
of cancer cells referred to as a spheroid embedded in a collagen gel. Although embedded 
spheroids in research are widespread, the scope of experiments performed is often limited 
to observations of growth. Therefore in this thesis, we developed methods to use an 
embedded spheroid model to study drug response, secondary cell types, and injury.  
Tumor associated macrophages are critical as stromal components intimately 
involved with the progression, invasion, and metastasis of cancer. To mimic clinically 
observed TAM localizations, two tumor cell/macrophage models are described. 
Macrophages are incorporated as a heterospheroid, a spheroid containing tumor cells and 
macrophages or diffusely seeded in the collagen surrounding a spheroid. The inclusion of 
macrophages as a heterospheroid changes the metabolic profile, indicative of synergistic 
growth, which is not observed in the diffuse model. The macrophages in the 
heterospheroid secrete cytokines that promote tumor cell growth and indicate Tam-like 
differentiation. In summary, macrophages incorporated in a heterospheroid are exposed 
	  	   viii 
to increased tumor cell contact, hypoxia and metabolic gradients, which promote TAM-
like characteristics.  
To investigate the effect of spheroid culture on chemotherapeutic efficacy, we 
evaluated the response of our spheroid model compared to cells diffusely seeded in 
collagen or a traditional monolayer. The spheroid model contains two populations, a core, 
a dense aggregate of cells, and a periphery, cells that have grown into the surrounding 
collagen. The core demonstrates chemoresistance, compared to cells in the spheroid 
periphery, diffusely seeded in collagen and monolayer. Preliminary research indicates 
that the core is associated with a higher percentage of chemoresistant cancer stem cells  
  Cancer is described as a wound that does not heal due to the presence of 
inflammation. To study the effect of a wound on a growing tumor, we developed a model 
for removing half of the spheroid and monitoring subsequent growth. Invasion into the 
collagen indicates increased growth and a microarray was performed to investigate 
relative changes in expression. In conclusion, we have demonstrated the utility of 
embedded spheroids in several cancer research applications. 
 
  
	  	   ix 
TABLE OF CONTENTS 
 
DEDICATION ................................................................................................................... iv	  
ACKNOWLEDGMENTS .................................................................................................. v	  
ABSTRACT ...................................................................................................................... vii	  
TABLE OF CONTENTS ................................................................................................... ix	  
LIST OF FIGURES .......................................................................................................... xii	  
LIST OF ABBREVIATIONS ........................................................................................... xx	  
Chapter 1: Embedded Spheroids as Models of the Cancer Microenvironment .................. 1	  
Tumor Microenvironment and Why the Monolayer Does Not Model It ........................ 1	  
The Non-embedded Spheroid as a Tumor Model ........................................................... 3	  
Translatable Improvements to non-Embedded Spheroids .............................................. 4	  
Embedded Spheroids ...................................................................................................... 7	  
Perspectives ................................................................................................................... 27	  
Chapter 2: Embedded Multicellular Spheroids as a Biomimetic 3D Cancer Model for 
Evaluating Drug and Drug-device Combinations ............................................................. 37	  
Abstract ......................................................................................................................... 37	  
Introduction ................................................................................................................... 38	  
Materials and Methods .................................................................................................. 40	  
Results ........................................................................................................................... 44	  
Discussion ..................................................................................................................... 47	  
	  	   x 
Conclusion .................................................................................................................... 52	  
Figures ........................................................................................................................... 53	  
Chapter 3: Mimicking the Tumor Microenvironment to Regulate Macrophage Phenotype 
Using an Embedded Spheroid ........................................................................................... 61	  
Abstract ......................................................................................................................... 61	  
Introduction ................................................................................................................... 62	  
Materials and Methods .................................................................................................. 65	  
Results ........................................................................................................................... 67	  
Discussion ..................................................................................................................... 71	  
Conclusion .................................................................................................................... 76	  
Figures ........................................................................................................................... 77	  
Chapter 4: Contributions of 3D Culture and Tumor Microenvironment to 
Chemoresistance in an Embedded Spheroid Model ......................................................... 84	  
Abstract ......................................................................................................................... 84	  
Introduction ................................................................................................................... 85	  
Materials and Methods .................................................................................................. 88	  
Results ........................................................................................................................... 92	  
Discussion ..................................................................................................................... 95	  
Conclusion .................................................................................................................... 98	  
Figures ......................................................................................................................... 101	  
Chapter 5: A Novel Method for Modeling Biopsy within an Embedded Spheroid Model
 ......................................................................................................................................... 108	  
	  	   xi 
Abstract ....................................................................................................................... 108	  
Introduction ................................................................................................................. 108	  
Materials and Methods ................................................................................................ 110	  
Results ......................................................................................................................... 112	  
Discussion ................................................................................................................... 113	  
Conclusion .................................................................................................................. 115	  
BIBLIOGRAPHY ........................................................................................................... 120	  
CURRICULUM VITAE ................................................................................................. 141	  	  
  
	  	   xii 
LIST OF FIGURES 
Figure 1.1 Tumor Microenvironment is Modeled in Spheroids: ...................................... 31	  
The growth of malignant cells as a tumor leads to a distinct microenvironment that is 
characterized by gradients of metabolites, oxygen, and nutrients.  The multicellular 
spheroids recapitulate aspects of tumor growth 11. ................................................... 31	  
Figure 1.2 Spheroids as Model Tumors: ........................................................................... 32	  
Sutherland first developed spheroids in the 1970s using the rotator flask method. The 
spheroids imaged are derived from Chinese hamster lung imaged at 120x 19. ......... 32	  
Figure 1.3 Spheroid-based Models: .................................................................................. 33	  
The embedded spheroid provides the opportunity to incorporate multiple cell types either 
within the spheroid, in the collagen matrix, or on top of the collagen. This 
modularity has resulted in a number of complex, application specific models. ....... 33	  
Figure 1.4 Two Distinct Populations in Embedded Spheroids: ........................................ 34	  
Multiple researchers have observed the presence of two distinct subpopulations within a 
glioma embedded spheroid model. There is a dense core (identified by a circle on 
the left and an S on the right) and a migrating population (shown with a dashed 
circle on the left and an I on the right) 78,95. .............................................................. 34	  
Figure 1.5 Spheroids have been Utilized by a Number of Fields: .................................... 35	  
Spheroids have been used in a number of fields including cancer research, (top) 
angiogenic sprouting of endothelial cells, (middle) and artificial tenocytes with 
embedded tendon cells (bottom) 66,98,123. Despite the diverse applications the 
similarities of the micron level structures are apparent. ........................................... 35	  
	  	   xiii 
Figure 1.6 The Vascularized Spheroid: ............................................................................ 36	  
The combination of EC and cancer spheroids has lead to a fully vascularized spheroid. 
Fibroblasts in the stroma stabilize vasculature formation. Evidence of interaction is 
apparent as cancer cells (green) can be seen within vasculature lumens (red) 119. ... 36	  
Figure 2.1. Creation of Embedded Spheroids: .................................................................. 53	  
Spheroid formation is encouraged by placing a suspension of cells (red) in media (pink) 
on agarose (yellow) coated wells. After 72 hours, a spheroid is formed, and then 
transferred into a collagen gel. .................................................................................. 53	  
Figure 2.2. Controllable Spheroid Size: ............................................................................ 54	  
Spheroid size can be controlled by varying cell seeding number. Sizing based on cell 
seeding number was demonstrated with both bone (top) and breast (bottom) cancer 
cells. .......................................................................................................................... 54	  
Figure 2.3. U2OS Spheroid Growth in Collagen: ............................................................. 55	  
Bone cancer spheroids grown in collagen gels with varying mechanical properties 
demonstrated the most growth in 3–4 mg/mL, growing less in both stiffer and 
weaker gels. ............................................................................................................... 55	  
Figure 2.4. MDA-MB 231 Spheroid Growth in Collagen: ............................................... 56	  
Breast cancer spheroids grown in collagen gels with varying mechanical properties 
demonstrated the most growth in the weakest collagen gels. ................................... 56	  
Figure 2.5. Pattern of Metabolic Activity: ........................................................................ 57	  
A spheroid in collagen was stained with a calcein based stain (green) to show 
metabolically active cells and an ethidium based stain (red) to demonstrate cells with 
	  	   xiv 
a compromised membrane. The red staining on the interior indicates a mostly dead 
core, whereas the green cells shows a metabolically active outer ring of cells. The 
inset quantitatively demonstrates that 85.5% of the spheroid is alive after 3 days via 
FACS. ........................................................................................................................ 57	  
Figure 2.6. Metabolic Activity of Spheroids: ................................................................... 58	  
Disaggregated spheroids were plated in a monolayer and the metabolic activity was 
compared to cells grown only in a monolayer. Although there were approximately 
60,000 cells, the overall metabolic level is comparable to 30,000 cells. .................. 58	  
Figure 2.7. Nanoparticle Penetration: ............................................................................... 59	  
Within 24 hours fluorescently labeled nanoparticles were able to fully penetrate a 20,000 
cell MDA-MB 231 spheroid. Scale bar is 100 µm. .................................................. 59	  
Figure 2.8. Spheroid Treatment with Nanoparticles: ........................................................ 60	  
Paclitaxel, a chemotherapeutic drug was delivered via bolus dose or nanoparticles for 24 
hours before the treatment was removed. The nanoparticle delivery method was the 
most effective at reducing spheroid size. .................................................................. 60	  
Figure 3.1 Macrophage Incorporation into Spheroid Model: ........................................... 77	  
Starting with an embedded spheroid model, the influence of macrophages (shown in 
green) was studied using four different component models (A). The first was a 
breast cancer spheroid (shown in red) embedded in a collagen gel (left). The second 
model consists of diffusely embedded macrophages within a collagen gel. The third 
model combines these with a spheroid surrounded by diffusely seeded macrophages 
within a collagen gel. The fourth model is a heterospheroid composed of both cell 
	  	   xv 
types. B) Heterospheroids are formed by including breast cancer cells and 
macrophages during spheroid formation on agarose in various ratios (bottom). ..... 77	  
Figure 3.2 Heterospheroid Formation: .............................................................................. 78	  
Macrophages were incorporated during spheroid formation to form a heterospheroid with 
a defined number of macrophages. Images show spheroids with tumor cells and 0 
(A), 1,000 (B), or 5,000 (C) macrophages. D) Inclusion of a greater number of 
macrophages resulted in increased spheroid diameter. E) A stained image with 
tumor (green) and macrophage (red) cells demonstrate a homogeneous mixture 
throughout the spheroid. The scale bar is 100 µm for all images. ............................ 78	  
Figure 3.3 Collagen Embedded Models: .......................................................................... 79	  
A spheroid composed of 10,000 tumor cells (10T) grows into collagen over eight days as 
a homogeneous structure. A heterospheroid with 10,000 tumor cells and 5,000 
macrophages (10T5M) forms a large but uniform structure resembling 10T. Both 
systems containing diffusely embedded macrophage have large clusters of 
macrophages present by day eight, with spheroid growth in the 10dT5M model 
appearing uninterrupted. All scale bars are 500 µm. ................................................ 79	  
Figure 3.4 Synergistic Growth in Spheroid Systems: ....................................................... 80	  
The presence of oxygen provides an indication of overall metabolic activity and cell 
growth rate. The method of macrophage incorporation results in starkly different 
oxygen consumption patterns. The heterospheroid demonstrates a faster decrease in 
oxygen presence compared to the diffuse model, suggesting a synergistic growth 
	  	   xvi 
pattern due to the interactions of the two cell types within a heterospheroid model 
(n=6). ......................................................................................................................... 80	  
Figure 3.5 Cytokine Based Interaction of Macrophages and Tumor Cells: ..................... 81	  
A) EGF concentration detected by ELISA is greatest in the heterospheroid system 
compared to any of the other systems (p<.005). B) Addition of an EGFR inhibitor at 
concentrations from 0.2–200 nM increased the oxygen presence in 10T5M systems 
by disrupting the EGF/EGFR interaction. The oxygen presence of untreated 10T5M 
is statistically different (p<0.005) from treatments of 200 nM. (* Indicates p<0.005.)
 ................................................................................................................................... 81	  
Figure 3.6 Cytokine Based Interaction of Macrophages and Tumor Cells: ..................... 82	  
An EGFR inhibitor at concentrations from 0.2–200 nM had no effect on the oxygen 
presence in 10Td5M system (top) or 10T system (bottom). Thus indicating the lack 
of EGF/EGFR interaction within this system. .......................................................... 82	  
Figure 3.7 Heterospheroid Enhances TAM Conversion: .................................................. 83	  
Secretion of IL-10 indicates the alternative M2 activation pathway associated with 
TAMs. Heterospheroids generated the highest concentration of IL-10, statistically 
different from all other systems (p<0.05). ................................................................ 83	  
Figure 4.1 Models for Drug Efficacy Evaluation: .......................................................... 101	  
The MDA-MB 231 cells were used in three models. The left is a monolayer. The middle 
is a 3D system with cells diffusely embedded in a collagen gel. The third model is a 
spheroid embedded in collagen with two discrete populations, a core (red) and 
periphery cells (purple). .......................................................................................... 101	  
	  	   xvii 
Figure 4.2 Morphological Drug Response of Systems: .................................................. 102	  
The systems of MDA-MB 231 cells were imaged after 72 hour drug exposure followed 
by 72 hour recovery. Following treatment, the monolayer experienced a decrease in 
overall cell number with an increase in large, rounded cells. When the diffuse 3D 
model was treated, morphological differences are subtle. However there appears to 
be an increase in large, rounded cells after treatment with either drug. Spheroids 
treated with paclitaxel experienced drastically reduced cell invasion into the 
collagen. Cisplatin treatment had a less dramatic effect on overall collagen invasion.
 ................................................................................................................................. 102	  
Figure 4.3 Monolayer Drug Response: ........................................................................... 103	  
The monolayer IC50 values for paclitaxel (top) and cisplatin (bottom) are 4.81 ng/mL 
and 0.987 µg/mL, respectively. ............................................................................... 103	  
Figure 4.4 Drug Efficacy in Different Populations: ........................................................ 104	  
A) After treatment with collagenase the periphery population is disaggregated into a 
suspension. The core is then removed and disaggregated with trypsin (B). The core 
and periphery populations are disaggregated and then plated in a monolayer. The 
relative viability demonstrates the ability of the core to resist apoptosis after 
treatment with paclitaxel (B) or cisplatin (C). The monolayer is the most sensitive to 
treatment with either drug. The spheroid periphery and diffuse 3D system are more 
resistant than the monolayer to either drug, but less resistant than the core. .......... 104	  
Figure 4.5 Spheroid Growth After Treatment: ............................................................... 105	  
	  	   xviii 
A) After treatment the core can be separated from the periphery and reseeded into 
collagen.  B) When reseeded into collagen after treatment, the growth of the core is 
retarded but not prevented by cisplatin (p<0.01). Paclitaxel treatment does not 
significantly decrease growth. C) All cores seeded into new collagen gels 
demonstrated some growth. All scale bars are 500 µm. ......................................... 105	  
Figure 4.6 Paclitaxel Oregon Green Penetration: ........................................................... 106	  
The presence of paclitaxel Oregon green in the monolayer and core indicates the decrease 
efficacy is not due to lack of availability. ............................................................... 106	  
Figure 4.7 Enrichment of CSCs in the Core: .................................................................. 107	  
There is a higher percentage of CSCs in the core compared to the periphery as 
demonstrated by Aldefluor assay (left) and mammosphere assay (right). .............. 107	  
Figure 5.1 The Biopsy Model: ........................................................................................ 116	  
This model creates an injury in an embedded spheroid. A spheroid of CS-1 cells (red) is 
cut on the third day of culture. Approximately 50% of the spheroid and surrounding 
collagen (tan) are removed. Fresh collagen is filled into the vacant area, and growth 
is monitored over the next five days. ...................................................................... 116	  
Figure 5.2 Spheroid Growth After Injury: ...................................................................... 117	  
A) The sarcoma spheroid is cut on the third day in collagen and new collaged is filled 
into the void. B) Images on the eighth day in collagen demonstrate growth into both 
the “cut” and “control” side of the spheroid. C) Invasion from day three to day eight 
was measured. Growth from the cut side was statistically higher (p<0.01) than the 
control side (n=4). ................................................................................................... 117	  
	  	   xix 
Figure 5.3 Method Validation: ........................................................................................ 118	  
In order to confirm that the injury model was reproducible, the percentage of the spheroid 
was quantified by measuring DNA concentration of an injured spheroid. The 
average percentage cut was 46.8±13.6% with a range of 30–59% of the spheroid 
remaining (n=5). ..................................................................................................... 118	  
Figure 5.4 Genetic Changes After Mechanical Injury: ................................................... 119	  
In order to understand the downstream effects of mechanical perturbation on an 
embedded spheroid model, a microarray was used to look at changes in expression. 
Of the 1,086 genes that demonstrated a change in expression, these four are linked 
with differentiation, growth and cancer stem cells. ................................................ 119	  	  
 
 
 
  
	  	   xx 
LIST OF ABBREVIATIONS 
°C ................................................................................................................. degrees Celsius 
µg ........................................................................................................................ Microgram 
µL .......................................................................................................................... Microliter 
µm .............................................................................................................................. Micron 
µM ...................................................................................................................... Micromolar 
10T .......................................................................................... 10,000 Tumor Cell Spheroid 
10T1M ............................................ 10,000 Tumor Cell/1,000 Macrophage Heterospheroid 
10T5M ............................................ 10,000 Tumor Cell/5,000 Macrophage Heterospheroid 
10Td1R ................. 10,000 Tumor Cell Spheroid with 1,000 Macrophages in the Collagen 
10Td5R ................. 10,000 Tumor Cell Spheroid with 5,000 Macrophages in the Collagen 
2D .............................................................................................................. Two Dimensional 
3D ............................................................................................................ Three Dimensional 
ALDH .......................................................................................... Aldehyde Dehydrogenase 
ALDH18A1 ............................................... Aldehyde Dehydrogenase18 family member A1 
ATCC ............................................................................. American Type Culture Collection 
BAE ............................................................................................. Bovine Aortic Endothelial 
BRDU ................................................................................................... Bromodeoxyuridine 
CAF ....................................................................................... Cancer Associated Fibroblasts 
CCL-17 ............................................................................ Chemokine C-C Motif Ligand 17 
CCL-22 ............................................................................ Chemokine C-C Motif Ligand 22 
COX-2 ...................................................................................................... Cyclooxygenase-2 
	  	   xxi 
CSF-1 ....................................................................................... Colony Stimulating Factor 1 
d1R ......................................................... 1,000 Macrophages Diffusely Seeded in Collagen 
d5R ......................................................... 5,000 Macrophages Diffusely Seeded in Collagen 
DNA ................................................................................................. Deoxyribonucleic Acid 
E2 ..................................................................................................................... 17β Estradiol 
EC ............................................................................................................... Endothelial Cell 
ECM ...................................................................................................... Extracellular Matrix 
EGF .............................................................................................. Epidermal Growth Factor 
EGFR ............................................................................ Epidermal Growth Factor Receptor 
ELISA ..................................................................... Enzyme-Linked Immunosorbent Assay 
eNP ................................................................................................... Expansile Nanoparticle 
EMT .......................................................................... Epithelial to Mesenchymal Transition 
FACS ............................................................................ Fluorescence-activated Cell Sorting 
GBM ............................................................................................ Glioblastoma Multiforme 
GFP ............................................................................................. Green Fluorescent Protein 
HIF ............................................................................................... Hypoxia Inducible Factor 
HUVEC ................................................................. Human Umbilical Vein Endothelial Cell 
IFN-γ ........................................................................................................ Interferon Gamma 
IL-6 ................................................................................................................... Interleukin 6 
IL-10 ............................................................................................................... Interleukin 10 
LPS ......................................................................................................... Lipopolysaccharide 
MCL1 ........................................................................................... Myeloid Cell Leukemia 1 
	  	   xxii 
mg ......................................................................................................................... Milligram 
mL ........................................................................................................................... Milliliter 
mM ....................................................................................................................... Millimolar 
mm ....................................................................................................................... Millimeter 
MPA ...................................................................... Progestin Medroxyprogesterone Acetate 
mRNA ..................................................................................... Messenger Ribonucleic Acid 
MTS ........ (3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)- 
  ..................................................................................................................... 2H-tetrazolium) 
MTT ................................ (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
nm ........................................................................................................................ Nanometer 
Pax .......................................................................................................................... Paclitaxel 
PDMS .................................................................................................. Polydimethylsiloxane 
pg ............................................................................................................................ Picogram 
qrt-PCR .............................................. Quantitative Real Time Polymerase Chain Reaction 
RNA .......................................................................................................... Ribonucleic Acid 
RNAi ..................................................................................... Ribonucleic Acid Interference 
siRNA ........................................................................... Small Interfering Ribonucleic Acid 
RND3 ................................................................................................. Rho Family GTPase 3 
rt-PCR ................................................... Reverse Transcription Polymerase Chain Reaction 
SMC .................................................................................................... Smooth Muscle Cells 
TAM .................................................................................... Tumor Associated Macrophage 
TGF-β ............................................................................. Transforming Growth Factor-Beta 
	  	   xxiii 
TGF-β ........................................ Transforming Growth Factor-Beta-1 Induced Transcript 1 
TNFRSF12A  ..................................... Tumor Necrosis Factor Receptor Super Family 12A 
TRAIL .................................... Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand 
UV ........................................................................................................................ Ultraviolet 
VEGF .......................................................................... Vascular Endothelial Growth Factor
	  	  
1 
Chapter 1: Embedded Spheroids as Models of the Cancer Microenvironment 
 
Tumor Microenvironment and Why the Monolayer Does Not Model It 
Tumors do not exist as a homogeneous population of malignant cells, alike in 
their collection of mutations. Rather a tumor is an organ characterized by changes in the 
microenvironment resulting from the interplay between a heterogeneous population of 
malignant cells and their assorted support of endothelial, tumor associated macrophages, 
cancer associated fibroblasts, pericytes and immune cells. However, we routinely use 
artificially polarized cells spreading on treated polystyrene as our first round of testing 
for research in cancer biology, cancer immunology, drug delivery, and novel drug 
discovery.  
 Monolayer cell culture has a number of downstream effects that differentiate it 
from cells in a tumor microenvironment. Before addressing the characteristics of a tumor 
microenvironment, the 2D nature of a monolayer substantially differentiates it from a 3D 
in vivo setting. The planar attachment surface constrains the cell geometry resulting in 
extreme spreading, unlike the rounded morphology present in 3D systems 1. The effect of 
this artificial geometry is a loss of polarity normally present in epithelial cells 2. This 
results in cells that are different on a genetic 3, and proteomic 4 level. A review of genetic 
differences in cells cultured in 2D versus 3D found upregulation in three categories 1) 
cell cycling, 2) metabolism and 3) turnover of macromolecules, thus enabling enhanced 
proliferation 2. For applications in drug delivery and discovery, the change from 2D to 3D 
dramatically increases the robustness of a cell to toxicity in both normal and cancerous 
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contexts, underscoring the need for 3D models 5,6. 
 Beyond the malignant cells, there are both cellular and acellular elements 
composing the stroma, which dynamically interact with the malignant cells. Thus, 
contributions from both stromal and malignant cells can promote cancer initiation, 
growth and progression 7. For example the inflammation that characterizes stroma is now 
recognized as inducing cancer 8. Conversely, a normalized stroma can revert a malignant 
phenotype in a 3D system, introducing the idea of treating the microenvironment to 
reverse malignancy 9,10. The progression of a polarized epithelium to a carcinoma can be 
documented through changes in the surrounding stroma such as stroma activation, 
degradation of ECM components, increase in immune components and breakdown of the 
basement membrane 7. Therefore, an ideal cancer model would allow inclusion of stromal 
components. 
 The last factor that separates cells in a monolayer from a tumor is the tumor 
macrostructure and the microenvironment that it inhabits. An avascular tumor or small 
micrometastasis under approximately 2 mm3 is characterized by gradients of metabolites, 
catabolites, and oxygenation, with proliferation at the edges and necrosis at the core as 
exhibited in Figure 1.1 11. The macrostructure dictates a microenvironment that differs 
from normal tissue in terms of oxygenation, perfusion, pH and metabolic states 12. After 
reaching a size of 1–2 mm3, diffusion supplies an insufficient amount of oxygen for the 
tumor resulting in a hypoxic state 13. Linked to hypoxia, the extracellular pH of a tumor is 
often lower (6–7) when compared to normal tissue (7.4) due to the use of glycolysis as an 
energy source for hypoxic cells 14. Hypoxia triggers upregulation of HIF, which initiates 
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the release of pro angiogenic factors that stimulate angiogenesis 15. However the poor 
development of a mature vasculature systems, translates to hypoxic regions even in 
vascularized tumors. The result is a heterogeneous range of metabolic states where 
actively cycling cells are adjacent to capillaries whereas distant cells become quiescent 
and possible necrotic or apoptotic.  
As the scientific community gains insights into the fundamental differences 
separating a tumor from normal tissue, they offer tempting targets for novel therapeutics. 
There are reviews highlighting treatments aimed at tumor microenvironment 12, cellular 
stromal components 16 including tumor associated macrophages (TAMS) 17 and cancer 
associated fibroblasts (CAFs) 18. Based upon the premise that a monolayer poorly models 
a tumor, this chapter review starts off by discussing the advantages of embedded 
spheroids as cancer models. It will then cover the contributions of embedded spheroids to 
several areas of cancer research including cancer biology, immunology, drug screening 
and delivery. Then, the utility of analytical methods used on embedded spheroids in other 
fields will be discussed as they pertain to cancer research. Finally, we will give our 
perspectives on how to fully exploit embedded spheroids as a cancer model moving 
forward.  
 
The Non-embedded Spheroid as a Tumor Model 
 In 1971 Sutherland, et al. presented spheroids as a model of nodular carcinoma. 
Spheroids were formed upon the basis of denying cells external attachment sites besides 
other cells as shown in Figure 1.2 19. Rotator flasks formed spheroids of 150–370 µm in 
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diameter with culture for up to 24 days. Upon reaching a diameter of 200 µm, necrosis 
developed in the center of the aggregate. Spheroids with diameters over 250 µm 
developed three zones 1) the first 75 µm of rapidly dividing cells in the periphery, 2) an 
intermediate zone of slower division, and 3) a necrotic zone in the center, which resemble 
the macrostructure of some human and animal carcinomas as shown in Figure 1.1. In 
addition to spinner flasks, multiple fabrications strategies are routinely used, all of which 
are based on denying cells attachment sites. The hanging drop method consists of 
inverting a droplet containing cells, which was first presented in 1907 in the field of 
nerve regeneration 20. This technique is prevalent and has since been commercialized to 
increase ease. Another popular method is the liquid overlay technique where a non-
adherent substrate such as agarose/agar or poly-HEMA coats a well to induce aggregation 
21. The inclusion of ECM supplements increase the applicable cell types, and regularity of 
formation 22 and micropatterned substrates increase the control over size and feasibility of 
complex shapes  23. Shen, et al. mimicked the effect of micropatterned substrates by using 
a self-assembled layer of glass beads to form PDMS microcavities 24.  An alternate 
approach to multicellular aggregates includes the use of microfluidics to form complex 
3D structures 25,26. Despite the lack of an ECM mimic, spheroids have proven themselves 
as a robust, scalable model that are widely used in existing literature.  
 
Translatable Improvements to non-Embedded Spheroids 
Although the subject matter at hand is embedded spheroids, or those that provide 
exogenous ECM mimics, significant progress have been made in increasing the 
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physiological relevance of and the ease of use for spheroids. The transition from non-
embedded to embedded could utilize a number of advances. Therefore improvements in 
analysis and preparation will be highlighted if applicable to embedded spheroids. 
 
A. Incorporation of Multiple Cell Types  
Within the tumor milieu, there are a number of non-malignant cell types affecting 
cancer invasion, growth and metastasis. These stromal cell types are often of significant 
interest for both understanding cancer biology, and as a target for chemotherapeutics. 
Ksiazkiewicz, et al. used spheroids to separately model the infiltration of tumor 
associated macrophages (TAMs) into the fibroblast-rich stroma versus malignant breast 
carcinoma 27. Spheroids composed of either immortalized breast cancer lines or breast 
tumor derived fibroblasts were used to model the tumor and stroma, respectively. Only 
one of the five breast cancer lines tested had monocyte infiltration comparable to the 
highly infiltrated CAF-based spheroids, possibly due to CAF/monocyte CCL2-
CCR2A/2B interaction. Multiple iterations of a monocyte or TAM-infiltrated cancer 
spheroids have further elucidated TAM/cancer cell interactions 28–30. The same method of 
exposing invasive cells to an intact spheroid has also been used to model highly invasive 
glioblastoma cells infiltrating spheroids of mature brain aggregates 31,32. To recapitulate 
the microenvironment of the invading tumor, a GBM spheroid was cultured next to a 
spheroid of mature brain aggregates, and selective staining allowed visualization of 
individual GBM cells invading the mature tissue 33.  
An alternate route to incorporating stromal cells within a spheroid uses two (or 
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more) cell types in the initial suspension prior to a standard technique such as liquid 
overlay. A heterospheroid composed of glioblastoma and endothelial cells formed a ring 
of the endothelial cells surrounding the center mass of glioblastoma cells 34. Using that 
model Ho, et al. demonstrated the selective targeting of endothelial cells by their 
tumstatin- iron oxide nanoparticles. Steven, et al. published an inVERT method that can 
be used to make complicated microtissues including different type of heterospheroid 
architectures 35. Although used to induce hepatic function, they created interpenetrating 
stromal cells versus a core and shell morphology. These approaches are not limited to 
stromal cells, but can also be used to model the heterogeneous population, and thus drug 
responsiveness, invasiveness and metastatic ability of cancer cells. 
 
B.  Spheroids Interacting with a 2D System 
 In order to investigate cell/ECM interactions without using an embedded system, 
spheroids are often placed upon ECM coated surfaces. Beaune, et al. cultured lymph node 
cancer prostrate spheroids on fibronectin coated glass to study mechanisms of cell escape 
from aggregates with strong cell-cell adhesions 36. Upon cell escape they observed the 
formation of membrane tubes capable of transport that tethered escaping cells to the 
aggregate. Membrane rupture or relaxation resulted in successful cell escape or return to 
the aggregate, respectively. Burleson, et al. exposed patient ovarian carcinoma ascite 
derived spheroids to thin layers of laminin, fibronectin, collagen I, and collagen IV 37. 
Spheroids exhibited greater adherence to fibronectin and type I collagen versus laminin 
and collagen IV. β1 integrin partially mediated adherence to both ECM proteins and 
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mesothelial monolayers. This provides a mechanism of ovarian cancer dissemination for 
cells in the ascite fluid in clinical cases. However, most solid tumors are enveloped by 
and interact with the surrounding ECM. One approach suited to embryo development, 
allows a spheroid of a human trophoblast cell line to invade a 3D environment where 
epithelial cells grew on top of a fibrin-agarose matrix with embedded human endometrial 
stroma cells 38. When treated with E2 and MPA, spheroid attachment was enhanced and 
complete invasion through the epithelial layer was observed. The multicellular system 
offers an opportunity to study embryonic implantation events, where the end result is a 
fully embedded system.  
 
Embedded Spheroids 
 Moving into a fully embedded system offers opportunities to mimic a tumor 
environment to facilitate physiological cellular interactions, metabolism, growth and 
invasion. Therefore, we will highlight both novel systems and analysis methods in the 
spheroid field that are either within or applicable to the study of cancer. In this review, 
embedding environments of agarose, matrigel, fibrin, animal models, and the most 
popular- collagen will be discussed. Although there are many stimulating theoretical 
models and simulations, this review will focus on experimental work 39–44.  
 
A. Spheroids Embedded in Agarose 
Agarose is traditionally used as a non-adherent material in the liquid overlay 
spheroid method, however the same non-adhesive property can be useful for embedding. 
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It’s easily controlled mechanical properties and resistance to cell digestion make it ideal 
for allowing spheroid growth in 3D while removing the opportunity for matrix 
remodeling. Therefore it was used for embedding human colon adenocarcinoma 
spheroids in different environments and modeling the associated changes in free energy 
45. Similarly, agarose constrained murine carcinoma spheroids were co-embedded with 
fluorescent beads 46. Changes in micro bead density allowed measurements of strain in 
the agarose, which afforded insights on stress distribution in spheroid growth. Areas of 
higher compressive stress correlated with decreased proliferation and induced apoptosis. 
 
B. Spheroids Implanted in Animals 
Although spheroids are often used to mimic the complexities of an in vivo 
environment while remaining in vitro, they can also be used in conjunction with animal 
models to yield interesting findings on tumor/stroma interaction. Agarose’s resistance to 
adhesion and remodeling lends itself to controlled spheroid/animal interactions. 
Macrophage infiltrated human breast cancer spheroids produced more VEGF and after 
implantation into a murine model, stimulated greater angiogenesis when compared to the 
spheroids lacking macrophages 29. Implantation in a dorsal skinfold chamber allowed for 
constant monitoring of blood vessel growth, and agarose coating prevented autologous 
macrophage infiltration. Similarly, agarose-coated adipose derived MSC spheroids were 
placed in a macroencapsulation device to promote angiogenesis and decrease foreign 
body response 47. In contrast, to promote invasion into native tissue uncoated human 
glioblastoma (GBM) spheroids were embedded within murine models 48. Using clinical 
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imaging modalities, they found C-MET to be applicable in imaging vasculature 
remodeling and proliferation in a vascularized tumor. In contrast, an invasive, non-
angiogenic phenotype was poorly imaged using existing techniques. Clinical imaging is a 
particularly attractive application for spheroid in animal models, as it lends itself to 
controlled tumor structure, but incorporates the challenges of imaging in a living 
organism. 
 
C. Spheroids Embedded in Matrigel 
To replicate the milieu of ECM proteins present at a tumor in an in vitro setting, 
matrigel/reconstituted basement membrane can be used as both a matrix and additive to 
aid in spheroid formation. While some cell lines form dense macrocellular structures, 
others will form loose aggregates poorly suited to modeling a tumor. Ivascu, et al. 
included small amounts of matrigel in the liquid overlay technique to extend the cell lines 
suitable for spheroid culture 22. 
Matrigel is not a prevalent choice for embedding, perhaps due to its poor 
mechanical properties when compared to tissue. However, its biological properties make 
it suitable for recapitulating differentiation. For example, human pancreatic ductal 
adenocarcinoma cells formed hollow spheroids, and when implanted into matrigel, 
formed ductal structures, making it a useful in vitro model of pancreatic epithelial cells 49. 
The differentiation of spheroids derived from human embryonic stem cells termed 
embryoid bodies, also benefitted from long-term culture in matrigel 50. The three markers 
of a differentiated primate trophoblast, HCG, progesterone and estradiol-17 β increased 
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after approximately 20 days in 3D culture, with sustained elevation over 30 days. In 
contrast, embryoid bodies grown in suspension only demonstrated short-term elevation of 
differentiation markers, but not sustained elevation. In spheroid research, matrigel’s 
primary use is in spheroid formation aid, although for developmental biology, it has 
utility as a differentiation inducing matrix. 
 
D. Spheroids Embedded in Collagen for Cancer Research 
Collagen is the most prevalent embedding material as it is both an ECM 
component, and upregulated within a tumor microenvironment. Use is further facilitated 
due to facile modulation of mechanical strength, pore size and fibril fraction through 
concentration 51. Commonly, spheroids are prepared utilizing one of the methods, 
described earlier (hanging drop, liquid overlay, etc.) and transferred into a collagen gel. 
The first use of this technique for modeling tumors was reported by Tamaki, et al. 1997, 
but earlier in analogous non-cancer models for liver 52 and differentiation 53. While 
embedding increases the utility of the model, it does increase the time for individual 
implantation, and becomes a bottleneck after the high throughput methods of spheroid 
formation. One strategy automated the procedure by microinjecting a mixture of cells and 
the polymer polyvinylpyrrolidone in collagen gels 54. The polymer immobilized the cells 
at the injection site reducing time for spheroid formation. The spheroids were comparable 
to those produced by hanging-drop. This system was amenable to a variety of cell types 
and inclusion additives to ensure spheroid formation. An alternate strategy consisted of 
labeling cells with magnetic cationic liposomes and directing their growth in a 3D 
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collagen gel with a magnetized iron pin holder array 55. The center-to-center spacing of 
the aggregates was 250 µm, limiting the spheroid size (their aggregates had an average of 
25 cells) and assay length. While both approaches successfully adapted embedding to a 
high throughput assay, both relied on imaging as the basis for subsequent analysis. These 
systems’ contribution to cancer biology, drug response, differentiation and angiogenesis 
can be increased by the combination of high throughput approach with quantitative 
methods. The rest of this manuscript will devote itself to describing contributions to the 
stated fields, and the novel methods used. 
  
 1. Cancer Stroma Interactions 
The utility of embedded spheroids models in cancer biology lies in the modularity 
of the system to evaluate a given element of the microenvironment created. For example, 
the inclusion of fluorescent micro beads for microrheology lends itself to both classical 
rheological data, akin to bulk measurements, and localized matrix properties correlated to 
invasion of a spheroid 56. The use of in situ multi-photon imaging of collagen embedded 
glioma spheroids afforded high resolution images of cells during migration 57. 
Specifically, Hwang, et al. used GFP-actin, mitochondrial dye and ratiometric redox 
imaging of reduced NADH and oxidized FAD. They showed the creation of pools of 
actin during migration in 3D, but acknowledged that the long exposures (of 15 minutes) 
disrupted 40% of observed migrating cells. A quenched-fluorescent IV collagen shifted 
focus to the degradation of extracellular proteins in the basement membrane 58. The 
presence of fluorescent degradation products indicate the ability of spheroid cells (both 
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migrating and non-migrating populations) to disrupt the basement membrane. Such 
protein imaging techniques offer new insights into how cells remodel and move within a 
protein matrix. 
The combination of phenotypically different cancer lines, offers insights into how 
a heterogeneous tumor grows and invades within a 3D matrix. Carey, et al. combined the 
advantage of confocal reflectance to show matrix remodeling with a mixture of invasive 
(mesenchymal) and non-invasive (epithelial) breast cancer heterospheroids 59. Aggressive 
cells lines remodeled the collagen fibers in a radial pattern and created cell scale micro 
tracks, to allow the non-proteolytic invasion of the non-invasive line. Inhibitors of MMP 
and ROCK based contractility prevented non-proteolytic invasion of epithelial cells in all 
matrices, and mesenchymal cell invasion in lower (but not higher) concentration 
collagen. A similar heterospheroid system determined that the more aggressive line 
initially localized to the spheroid periphery, however after extended culture (for four 
days) the less aggressive line composed the majority of the spheroid 60.  
The inclusion of multiple cell types is not limited to tumorigenic cells, but extends 
to secondary cell types, typically CAFs and TAMs. Some research focus on models of 
stromal cell types without including malignant cells such as a collagen embedded CAF 
spheroids 61 or non-embedded TAM-invaded CAF spheroids 27. However the most 
prevalent iteration combines malignant cells with its analogous stromal cells. One 
embedded system studied invasion retardants aimed at stromal cells in a 2:1 glioma and 
microglia (brain-specific TAMs) heterospheroid 62. Microglia stimulated with LPS and 
IFN-γ decreased the glioma-led collagen invasion, as it skewed the microglia towards an 
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anti-tumor activation pathway. However the decrease in invasion was not observed with 
unstimulated microglia or single cells spheroids regardless of stimulants. A 
heterospheroid system focused on fibroblasts combined 1:1 CAFs and hepatic cancer 
cells to test the effect of stromal fibroblasts on doxorubicin response 63. Heterospheroids 
had the most robust response compared to single cell type spheroids or monolayer 
systems, as measured by the Alamar blue assay. Heterospheroids are not the only way to 
incorporate multiple cell types as demonstrated in Figure 1.3. One downside of the 
heterospheroid approach is that the contributions of indirect versus direct contact are not 
easily separated. The previously mentioned magnetic system by Okachi, et al., was 
further developed to elucidate the differences by including fibroblasts in direct contact 
with cancer cells in a heterospheroid or indirect contact with fibroblasts homogeneously 
distributed around the cancer cells as shown in Figure 1.3b 64. Invasion length and area 
was significantly higher with the direct contact arrays, highlighting the need for models 
that can portray such subtle differences.  
Systems containing tumor support cells have great utility to novel 
immunotherapies or chemotherapeutics targeted against elements of the tumor stroma. 
Conversely, models incorporating non-malignant cells allow the demonstration of therapy 
specificity in affecting malignant cells, but not non-malignant cells. Vorsman, et al. 
developed a multi cell skin model of melanoma consisting of a top layer of keratinocytes, 
with a collagen embedded melanoma spheroid surrounded by diffusely seeded primary 
fibroblasts shown in Figure 1.3d 65. The combination of treatment with TRAIL and either 
cisplatin or UV-B as a sensitizer was tested in both the 3D model and single cell 2D 
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culture. For long term treatments, cisplatin and UV-B performed similarly in the 3D 
model and 2D culture. However, the 3D model revealed the greater potency of cisplatin 
as a TRAIL sensitizer in short-term treatments by reducing spheroid size and number, 
which was not observed in 2D culture. In both TRAIL/cisplatin and TRAIL/UV-B, 
selective induction of apoptosis was exhibited, as melanoctyes, keratinoctyes and 
fibroblasts remained largely unaffected when separately treated. Results such as this 
support the need for complex 3D models, since 2D models are not faithful predictors of 
3D results.  
 
 2. Cancer invasion 
The embedded spheroid model is often termed the spheroid invasion assay, 
describing its utility to studying mechanisms of cancer cell invasion into the ECM. The 
earliest embedded spheroid for cancer research monitored the invasion of glioma cells 
into collagen I via imaging 66. They quantified the presence and activity of 
metalloproteases for collagen IV and I within the media, and the subsequent decrease in 
invasion after MMP inhibitor treatment. Based upon this, they hypothesized that the 
mechanism of invasion was through degradation of collagen fibers, which was later 
supported by confocal reflectance images of the ECM 59. Invasion distance, area or 
individual cells invading as assessed by imaging remains the most prevalent spheroid 
characterization used by glioma 67–69 and breast 70–74 spheroids. Subsequent modifications 
involve the use of other imaging modalities such as MRI on iron labeled glioma 
spheroids 75. 
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Embedded spheroids have been characterized as having two populations, a 
migratory or invasive population and a non-migratory core in glioma 68,76–78 and 
melanoma 65 spheroids shown in Figure 1.4. This is a consequence of the two distinct 
microenvironments present, the former dominated by cell-matrix interactions and the 
latter by cell-cell contacts. In order to accurately assess the invasive capabilities of the 
migratory versus core population, Gole, et al. mechanically separated the two populations 
for characterization 79. Increased cathepsin B activity was observed in the invading 
population despite no upregulation at the mRNA (via rt-PCR) or proteomic level 
(measured in cell extracts by Elisa). A decrease in invasion was observed following 
treatment with a chemical inhibitor or siRNA. The research by Gole, et al. highlights the 
ability to separate populations within the model for further elucidation of how 
microenvironment impacts cell invasion. 
The utility of embedded spheroids as an invasion model extends to complex 
pathways. Imaging, often in conjunction with staining of a spheroid is usually a small 
part of a larger study detailing the effects of a pathway inhibitor or knockdown on both 
invasion and viability. In this way, researchers demonstrated the efficacy of inhibitors of 
the SRC pathway in pre-metastatic but not post-metastatic melanoma spheroids 80. The 
inhibition of the MEK pathway affects STAT3, resulting in increased invasion in human 
melanoma spheroids 81. Melanoma spheroid growth into collagen implicated Rnd3 in 
invasion 82 and subsequently revealed BRAF inhibition affected Rnd3 expression and 
thus invasion 83. A similar approach has been used to study the link between AP-1 
components and TGF-β induced invasion in breast cancer 84. Reduced invasion of 
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squamous carcinoma spheroids after treatment with S100A4 RNAi helped demonstrate 
the role of S100A4 in both EMT and metastasis 85. Although the utility of spheroids is 
evident in this work, there is a great dependency on additional culture systems due to the 
lack of characterization methods amenable to embedded spheroid research. This often 
forces investigators to use imaging as the main evaluation of spheroid activity. 
Although image based analysis of spheroid size and growth are useful, the 
contradictory results in 2D versus 3D can require further characterization of the spheroid, 
as opposed to the assumption that 2D findings remain relevant in a 3D environment. To 
study the role of RhoA-directed mDia2 in invasion, Pettee, et al. used collagen embedded 
ovarian spheroids 86. mDia2 depletion enhanced invasion via an amoeboid transition, in 
contrast to untreated spheroids where mesenchymal invasion dominated, demonstrating 
that RhoA/mDia2 influences invasion type. To track protein levels of Rock and mDia2 in 
3D during spheroid formation, or after knockdown, Western blots were performed on 
spheroid lysates. Similarly, Western blots were used in conjunction with staining of colon 
cancer spheroids when studying the role of KRS in invasion 87. Since Western blots do 
not require whole cells, it is well suited to embedded systems, the main potential 
restriction being low cell numbers and thus low protein yields. The combination of 
observed invasion and measured protein levels within the same system ensures that 3D 
phenomena are supported by 3D protein expression.  
To circumvent insufficient protein levels, qrt-PCR can be exploited to investigate 
differences in transcription when studying complex pathways. The combination of 
observed invasion and rt-PCR has been extensively utilized by the Ten Dijke group in 
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studying the role of TGF-β induced invasion in breast cancer. Spheroids composed of 
MCF10a derivatives modeled tumors of increasing malignance 72. TGF-β induced 
invasion correlated to malignance 70. However, inhibitors and RNAi targeting Smad3 and 
Smad4 abrogated TGF-β induced invasion. Qrt-PCR of MMP-2 and MMP-9 
demonstrated TGF-β stimulated expression and dependence on Smad3 and Smad4. BMP-
7 inhibited invasion in the post metastatic, but not pre-malignant MCF10a derivatives 71. 
The mechanism of action was through inhibition of TGF- β induced expression of 
integrin αvβ3, which was necessary for invasion. Through rt-PCR they demonstrated the 
increase in αv and β3 in response to BMP-7, but not MMP-2. The ability of TGF- β to 
induce EMT was investigated by observing over expression of transcriptional repressors 
Snail and Slug after treatment with TGF- β 70. Furthermore, the over expression of Snail 
and Slug enhanced TGF- β induced invasion. Spheroids were used in a lesser extent when 
studying the inhibitory role of p53 on TGF- β induced invasion 73. Although more 
laborious than a monolayer, confirming expression changes in 3D is absolutely crucial. 
The spheroid invasion assay is based upon the principle that 3D spheroid culture 
maintains cells that are proteomically and genetically different from their monolayer 
counterparts. Thus the widespread use of nucleic acid and protein assays in conjunction 
with spheroid culture will serve to increase their utility.  
In contrast to the biological approaches discussed, Haeger, et al. approached 
invasion of melanoma and fibrosarcoma from a mechanical perspective 88. A number of 
studies have referenced different invasion modes in mesenchymal cells namely single cell 
versus collective invasion 86,89. By focusing on the matrix, as opposed to cells, Haegar at 
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el teased apart the differences between pore size and stiffness 88. To increase pore size, 
with minimal effect on stiffness, they gelled collagen at a lower temperature (21°C versus 
37°C) and quantified the changes with confocal reflectance images. Invasion was 
categorized as single cell or collective. In the high concentration (8 mg/mL) small pore 
collagen, they identified the collective leader/follower invasion demonstrated by Carey, 
et al. 59. However in the low concentration (2.5 mg/mL) large pore collagen, invasion 
occurred with single cells. In high concentration, large pore collagen, cell behavior 
correlated to pore size, not stiffness (which was higher than the 8 mg/mL 37°C gelled 
collagen) and invaded by single cells. Thus they demonstrated the plasticity of invasion 
in response to pore size. The recent publication by Ayuso, et al. proposed an additional 
tool for studying invasion, namely combining embedded spheroids with the controlled 
gradient capabilities of a microfluidic device 90. They showcased their system with 
simple gradients of serum that induced directional invasion of human oral squamous 
carcinoma and a glioblastoma line with collective and individual invasion, respectively. 
This platform could facilitate the study of invasion under the influence of chemoattractive 
or chemorepellant gradients.  
 
 3. Embedded Spheroids to Test Chemotherapeutic Efficacy 
The recapitulation of tumor macrostructure and environmental cues of hypoxia, 
cell-cell and cell-ECM contacts make spheroids an ideal model of the heterogeneity 
present in a tumor, and thus useful for evaluating chemotherapeutic efficacy. The 
incorporation of both 3D culture and tumor macrostructure impart a resistance greater 
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than 3D culture alone 91. One of the earliest evaluations of chemotherapeutic efficacy in 
embedded spheroids was the adjuvant gamma-linolenic acid tested in glioma spheroids 78. 
Efficacy was predominantly judged by invasion into collagen, and apoptosis calculated 
from staining with H&E, TUNEL and proliferating cell nuclear antigen. As with studies 
focused on invasion, there are a number of reports that use stained spheroids as a part of a 
larger study. DAPI staining was performed when elucidating the role of TM4SF5 in drug 
resistance and the use of anti TM4SF5 agents to enhance the efficacy of 
chemotherapeutics 92. Live/dead staining confirmed the susceptibility of a novel subtype 
of melanoma to imatinib 93. In squamous cell carcinoma spheroids, Basu, et al. 
determined the susceptibility of collective migration by E-cadherin positive cells versus 
infiltrative invasion by mesenchymal-like cells to different anti-neoplastic agents 89. 
Erlotinib and cetuximab targeted collective migration, which increased the infiltrative 
invasion. In the absence of mesenchymal like cells, erlotinib was effective. Animal-
derived breast spheroids were treated with cysteine cathepsin inhibitor in vivo (prior to 
harvest and spheroid formation) or in vitro as spheroids to demonstrate that 1) the 
inhibitor decreased invasion and 2) in vivo treatment did not induce in vitro resistance 94.  
Although invasion and migration are important metrics to be considered, a 
measurement of viability or proliferation is a crucial aspect of drug response. 
Chemotherapeutics that target rapid division or migration, such as paclitaxel will impact 
invasion. However, drugs that target DNA like cisplatin, are not biased based on 
metabolism or migration. Therefore a cisplatin treated spheroid might demonstrate 
decreased viability, but a lesser effect on invasion. An, et al. demonstrated this difference 
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when testing the effect of SAHA on glioma cells. SAHA dramatically reduces invasion 
into collagen, as quantified via imaging 95. The effect on invasion was partially due to an 
inability to reorganize the surrounding collagen and potentially to increased cell-cell 
adhesion. In order to measure the effect on proliferation, spheroids were disaggregated 
with collagenase and trypsin prior to treatment with CyQuant-GR dye, through which cell 
number can be calculated. The decrease in cell number after treatment indicated an 
invasion-independent effect on proliferation. Live/dead staining qualitatively showed the 
localization of apoptosis in the spheroid core. Quantitative assessment of cell death 
should be widely utilized in order to accurately evaluate independent effects of a drug on 
invasion and proliferation. 
Embedded spheroids are an ideal model to test nanoparticle efficacy as spheroids 
can be used to model mass transport issues through a dense multicellular aggregate. 
Nanoparticle penetration and subsequent efficacy has been extensively tested in non-
embedded spheroids reviewed here 96. However, analogous studies performed in 
embedded spheroids are rare. An, et al. demonstrated biocompatibility of PSS/PAH 
microcapsules in glioma spheroids by showing typical collagen invasion after treatment 
77. Light based treatments can be tested with spheroids, as the multi cell skin model tested 
the effect of UV-B in addition to cisplatin as discussed earlier 65. However, for bulk 
delivery devices such as meshes, wafers and patches, the media volume, might artificially 
concentrate the released drug.  	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E. Spheroids Embedded in Collagen and Fibrin in Other Research Areas 
 1. HUVEC Sprouting 
Although this manuscript focuses on spheroid applications in cancer research, 
spheroids have widespread utility to a number of research areas with some examples 
shown in Figure 1.5. One especially rich field of spheroid research has been the sprouting 
of endothelial cells during angiogenesis. The system is based on spheroids of human 
umbilical vein endothelial cells (HUVECs) or bovine aortic endothelial cells (BAE) that 
form a differentiated surface layer with an unorganized, apoptotic core through the liquid 
overlay method 97. The seminal paper that followed in 1999 by Korff and Augustin 
demonstrated that the collagen embedded spheroids spontaneously sprouted radial 
capillary-like protrusions that differentiate to form true capillary lumens (Figure 5b). 
Adjacent spheroids display directional sprouting and thus multiple spheroids can form 
large, complex structures. This manuscript was the first to demonstrate mechanically 
induced directional sprouting 98. Two quantifications of sprouting were presented: the 
lengths of the three longest protrusions, or the cumulative length of all protrusions. 
HUVECs have a lower angiogenic potential, and were recommended for testing 
exogenous stimulants, as was performed with VEGF and FGF-2. BAE cells have a higher 
angiogenic potential and were suitable for testing with angiogenic inhibitors. This assay 
and the recommended quantifications have been widely used in a number of publications 
in this field with slight or no modifications 99–107. Haspel, et al. supplemented observed 
sprout length with Western blots to analyze protein expression 108. In addition, an 
alternate method for spheroid formation and embedding was explored 109. 
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The designers of this system have continued to improve the model and explore its 
applications. Embedded spheroids have been used to create functional IC50 curves for 
approved drugs to ascertain any affect on angiogenesis 110. The model has been made 
more robust by the introduction of immortalized HUVECs, which reduce the inherent 
variability of primary-derived HUVECs due to donor and passage number 110. To model a 
mature blood vessels, smooth muscles cells were incorporated in a (1:1 or 4:1 
HUVEC:SMC) heterospheroid 111. The two cell types spontaneously differentiate into a 
core of SMCs and a surface layer of ECs in a calcium dependent manner. The inclusion 
of SMCs induces a mature EC phenotype indicated by an increase in junctional 
complexes, decreased PDGF-β expression, and decreased EC apoptosis. Exogenous 
VEGF failed to stimulate sprouting in 1:1 heterospheroids. Sprouting was achieved only 
by increasing the EC content (4:1) before VEGF treatment, indicative of crosstalk 
between ECs and SMCs. Successful sprouting of 1:1 heterospheroids required co-
stimulation by VEGF and Ang-2, an antagonist of Ang-1, which is expressed in SMCs as 
shown by rt-PCR. Ang-2 destabilizes the EC and mural cell interactions, to facilitate 
VEGF responsiveness. A heterospheroid with VEGF transduced SMCs and Ang-1 
transduced ECs resulted in coordinated sprouting 112. A spheroid composed of a mixture 
of chicken embryonic arterial cells demonstrated differentiation and sprouting of the 
myofibroblasts present without EC sprouting after the addition of VEGF, PDGF-BB and 
FGF-2 113. The implementation and modification of heterospheroids in the angiogenesis 
field has been widespread leading to multiple heterospheroid combinations. Similar to 
SMCs, human bone marrow or adipose derived stromal cells support the formation of 
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prevascular structures by HUVECs when formed as heterospheroids of HUVECs/BMSC 
or HUVEC/ASCs. The secretome of both BMSCs and ASCs was analyzed via ELISA, to 
find a number of trophic factors that stimulate EC growth. Primary human 
fibroblasts/HUVEC heterospheroids decreased HUVEC apoptosis, but also sprouting, 
which nevertheless bears promise for vascularizing engineered tissues 114. An attempt to 
similarly vascularize collagen-based bone grafts used suspended single osteoblasts 
around an endothelial cell spheroid 115. Osteoblasts inhibited the sprouting of HUVEC 
spheroids even with exogenous stimulation due to cell-cell contacts between the two cell 
types. However, endothelial progenitor cell spheroids sprouted with exogenous growth 
factors, despite the presence of osteoblasts, making it a prospect for vascularized bone 
grafts. 
The merging of the fields of cancer modeling and EC sprouting has resulted in the 
vascularized spheroid. The inclusion of vasculature enables modeling of later stage 
tumors as opposed to being limited to avascular early stage tumors. Initial attempts 
started with non-embedded melanoma/endothelial heterospheroids used to establish the 
anti angiogenic properties of resveratrol that were not observed in a monolayer 116. A 
second non-embedded heterospheroid demonstrated that the inclusions of murine ECs 
sensitized murine mammary cells to treatment with Taxol, but protected them from 
radiation 117. Non-embedded approaches remain limited by the lack of external matrix, 
since sprouting is not observed in its absence. The addition of both fibroblasts and ECM 
stabilized the endothelial cells. Correa, et al. showed increased sprouting in their three 
cell heterospheroids at a ratio of 2:2:1 (normal human dermal fibroblasts: MDA-MB 231 
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breast cancer line: HUVECs) where the fibroblasts mimicked mural cells 118. The 
incorporation of all three cell types as opposed to only the stromal cells (fibroblast and 
ECs) resulted in different response profiles to anti-angiogenic agents and traditional 
chemotherapeutics. The main metric for overall system response was mean sprout length, 
however they also independently tracked tumor cell growth with a luciferase line. 
Selective expression of shRNAs by cell type enabled the identification of MT1-MMP as 
regulating endothelial sprouting through expression in fibroblasts and ECs, but not tumor 
cells. A second approach formed heterospheroids from tumor and HUVECs with normal 
human lung fibroblasts embedded in a fibrin matrix as shown in Figure 6 119. Robust 
sprouting was evident, and one of the tumor lines (epithelial colon) tested was observed 
within the lumens of invading capillaries. Decreased oxygen presence, encouraged 
greater intravasation by the tumor cells, which they found to be partially regulated by an 
EMT driver, Slug. Models such as these advance the spheroid past the level of early 
tumor models by the inclusion of a functioning vasculature. The incorporation of a 
number of aspects of a tumor microenvironment simultaneously increases the treatment 
types that the spheroids can effectively test. Furthermore, the selective control either by 
luciferase, shRNA, 118 or siRNA 119 enabled monitoring of an individual cell type within 
a multiple cell system. 
Building off of the effect of tension on directional sprouting shown by Korff et al. 
98, Mason, et al. modified the stiffness of the collagen gel post-embedding using a non-
enzymatic glycation 120. The stiffness of 1.5 mg/mL gels was modified to levels of ~175–
730 Pa, depending on ribose concentration added. Importantly, gels between ~175–500 
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Pa have similar fibril size and arrangement, with stiffer gels having slightly larger fibers. 
BAE spheroids demonstrated higher sprouting in the stiffer collagen gels, indicative of 
the effect of mechanical environment on angiogenesis. A technique that decouples 
stiffness from density and fiber structure is of great utility in studying cancer invasion.  
 
2. Maintaining or Influencing Differentiation or maybe just Tissue 
Engineering 
 
Similar to endothelial cell sprouting, embedded spheroids can serve to 
differentiate stem cells along a preferred lineage or maintain the phenotype of primary 
cells when treated with the correct mixture of growth factors. Drawing inspiration from 
the EC sprouting assay, a similar assay was adapted to neurite growth. The supportive 
functions of Schwann cells are critical to neurite growth; however, 2D co-culture 
methods with and without contact did not dramatically increase neurite length 121. 
Moving into a 3D collagen embedded heterospheroid of 1:10 NG108-15 to neonatal rat 
Schwann cells almost tripled mean sprout length when compared to 2D 122. This 
highlights the importance of not just cell-cell contacts, but also 3D environment in 
recreating cell interactions. 
When seeking to maintain differentiation, the goal is to recreate a complex 
microenvironment that can influence cell behavior. One multiple cell system modeled 
skin by embedding dermal stem cells spheroids in collagen surrounded by fibroblasts 
with a layer of keratinocytes on the top. The dermal stem cells differentiated into 
epidermal melanocytes. When maintaining the differentiation of mature equine tenocytes, 
both matrix and growth factor additive proved important 123. Tenocyte spheroids 
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embedded in collagen demonstrated contraction and alignment when treated with low-
serum media containing TGF-β1, ascorbic acid and insulin, but not in agarose, or when 
treated with a high-serum media lacking additional growth factors shown in Figure 1.5c. 
When the applications endpoint is implantation, the matrix can do more than support 
function of embedded cells, but rather actively increase the viability post-transplant. Hou, 
et al. developed a collagen-filled polyurethane foam featured heparin-immobilized VEGF 
to address the main drawback of hepatocyte transplantation- low vascularization 124. The 
use of rat hepatocytes in a spheroid increased viability and albumin production (which 
are indicative of hepatocyte specific function) compared to the diffusely embedded 
hepatocytes 125. The increase in viability and vascularization after implantation in a rat 
model was further improved by the synergistic combination of spheroid macrostructure 
and application specific matrix. The use of fetal rat hepatocytes was also explored and 
although they induced greater angiogenesis, they were plagued by low viability 124. 
Spheroid culture is also applicable to skewing the differentiation of cells along a 
desired lineage. An early attempt of differentiating mammary leporine cells in a number 
of culture conditions found that spheroids embedded in collagen, or placed on top of 
floating collagen gels, recapitulated some aspects of a functioning mammary gland 53. 
While both formed fat droplets, and differentiated into two cell types, the floating gels 
had more microfilament rich cells, while the embedded spheroids formed large duct like 
structures. More recent efforts have focused on exploiting the differentiation capabilities 
of mesenchymal stem cells (MSC). When MSC spheroids were embedded in fibrin and 
treated with osteogenic media, they outperformed diffusely embedded cells in terms of 
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metabolism and resistance to apoptosis when cultured in hypoxic, serum-free conditions 
126. Importantly alkaline phosphatase, a marker of osteogenic potential did not 
significantly decrease, and calcium production was significantly higher. Fibrin-embedded 
MSC heterospheroids were encouraged along a cardiac pathway and used to treat post-
ischemic rats 127. Heterospheroids were formed by a two-step hanging drop method that is 
applicable to layered spheroid morphologies. First, a spheroid of subamnion cord-lining 
MSCs (15,000) is formed for three days and on the fourth day HUVECs (2,000) were 
added to form an outer layer. Each animal received approximately 150 fibrin-embedded 
spheroids, which increased ejection fraction, attenuated adverse left ventricle remodeling 
such as scarring, and increased vascularization. The differentiation of mature cells can be 
attempted by the same manipulation of culture conditions and cytokine exposure in a 
process called transdifferentiation. Collagen-embedded rat hepatocyte aggregates were 
transdifferentiated to resemble bile duct cells in a similar fashion as with the MSCs 128–
130. 
 
Perspectives 
 While embedded spheroids have served as useful models in cancer, angiogenesis 
and differentiation research, a lack of characterization methods hinders their total utility. 
While embedding increases the physiological relevance, it also increases the cost and 
complexity of the system. Thus spheroid model may not be amenable to the many 
techniques available for 2D systems. For example, spheroids with less than 10,000 
cells/system may require too many samples to achieve the quantities of genetic material, 
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protein or cells required for FACs, Western blots or mRNA chips analysis, which is 
further hampered by slowed growth in 3D compared to 2D systems 52,131. Increasing the 
spheroids per system, to maximize cell yields may introduce unwanted spheroid/spheroid 
interaction. Furthermore, harvest methods may be harsh or labor intensive due to the 
embedding material. Therefore there is a heavy reliance on imaging and subsequent 
analysis. Although there have been improvements to post-imaging analysis, the field of 
spheroid research could be furthered by widespread use of quantitative non-image based 
techniques 132.  
  Some researchers have sought to characterize spheroids with Western blots, 
Elisas, luciferase (correa), or rt-PCR, but all to often imaging is the main characterization 
method. Observational insights are then explored and confirmed in 2D. Thus we are 
using 2D to inform us about phenomena occurring in multicellular 3D aggregates. To 
address this, the widespread incorporation of new methods is paramount. Non-destructive 
methods to monitor viability such as oxoplates or luciferase expressing lines can help 
evaluate novel drugs, without presuming that invasion correlates to efficacy. Furthermore 
the use of cell lysates for analyzing protein or mRNA combines the advantage of 
characterizing cells in 3D without requiring disaggregation of the collagen. However 
disaggregating ECM and aggregates to acquire a suspension of cells enables the use of 
many standard biochemical procedures such as colorimetric viability assays, plate reader 
live/dead assays and FACS. Non-embedded spheroids have utilized these resources to 
push the capabilities of spheroids. Li et al., scaled up drug screening to a high throughput 
system in non-embedded spheroids by combining viability measurements with a 
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colorimetric assay and evidence of EMT through vimentin expression. The stable 
transfection of a vimentin promoter in a firefly luciferase reporter plasmid enabled facile 
quantification of vimentin expression (2011). They screened a panel of marine secondary 
metabolites for small molecules that regulate EMT without causing toxicity. FACs has 
been used on non-embedded spheroids, 133 and can facilitate quantification of uptake of 
fluorescently labeled drugs or nanoparticles and analysis of surface markers. The 
combination of uptake and viability studies is especially important to the evaluation of 
nanoparticles, in which non-embedded spheroids are prevalent, and embedded spheroids 
absent. With the widespread use of more quantitative characterization methods, entire 
papers can be devoted to studying the efficacy of a drug, influence of a pathway or 
materials based interaction in spheroids, as opposed to relegated to several figures of a 
larger study. 
 Although spheroids are used in a number of fields such as cancer research, 
vasculature development and phenotypic control of stem cells, there is very little 
crosstalk between these related fields. The models and methods used are easily 
translatable between fields, where the end goal is recapitulation of a microenvironment to 
influence cell phenotype. This is most striking when examining the research of Vorsman, 
et al. and Li, et al. 65,134. Both modeled skin using spheroids of melanoma or dermal stem 
cells surrounded by fibroblasts in a collagen gel with a layer of keratinocytes on the top. 
The melanoma system was used for drug testing, while the dermal stem cell system 
demonstrated their stemness by giving rise to differentiated epidermal melanocytes. The 
methods used are the same, but differ in only application. For example, vasculature 
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research has shown a willingness to embrace heterospheroids or multi cell type systems 
that seem less prevalent in the cancer field. Cancer models with CAFs and TAMs would 
be of tremendous utility in evaluating therapies aimed at these secondary cell types.  
Greater cross talk and adoption of methods between these related fields would ultimately 
increase the capability of spheroids to offer insights into uptake, metabolic activity, 
protein regulation and secondary cell interactions that have been under utilized.   
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Figure 1.1 Tumor Microenvironment is Modeled in Spheroids:  
The growth of malignant cells as a tumor leads to a distinct microenvironment that is 
characterized by gradients of metabolites, oxygen, and nutrients.  The multicellular 
spheroids recapitulate aspects of tumor growth 11. 	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Figure 1.2 Spheroids as Model Tumors:  
Sutherland first developed spheroids in the 1970s using the rotator flask method. The 
spheroids imaged are derived from Chinese hamster lung imaged at 120x 19. 	    
FIGURE I.-Wet-mount 
of multicell sphe-
roids. X 120 
FIGURE 2.-l\1ulticell 
spheroid after growth 
for 8 days. Diameter, 
250 po. Center con-
tains few necrotic 
cells. 
118 SUTHERLAND, McCREDIE, AND INCH 
 at Boston University on April 3, 2013
http://jnci.oxfordjournals.org/
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Figure 1.3 Spheroid-based Models:  
The embedded spheroid provides the opportunity to incorporate multiple cell types either 
within the spheroid, in the collagen matrix, or on top of the collagen. This modularity has 
resulted in a number of complex, application specific models. 	    
A B C D
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Figure 1.4 Two Distinct Populations in Embedded Spheroids:  
Multiple researchers have observed the presence of two distinct subpopulations within a 
glioma embedded spheroid model. There is a dense core (identified by a circle on the left 
and an S on the right) and a migrating population (shown with a dashed circle on the left 
and an I on the right) 78,95.   	    
At GLA concentrations between 250 and 1000 !M, the
invasive capacities of the glioma spheroids in all four cell
lines were significantly impaired, with only very small in-
creases in diameter occurring with the size at implantation
(Fig. 2). During incubation in the 1-mM solution of GLA
the C6 glioma spheroids were induced to fragment into
necrotic clusters and were measured at “zero” from Day 2
until the end of the experiment.
When examined using light microscopy before fixation,
there were no noticeable differences in the morphological
features of the invading cell population between the con-
trol and low-dose GLA gels. The control and lower-dose
(10–50 !M) GLA experiments showed a characteristic
thinning of the cell population at the periphery of the
spheroid mass, where cells move from the main spheroid
body to become part of the invading cell population (Fig.
3). In the three highest GLA concentrations (250–1000
!M) an absence of this thinning was shown, and detailed
histological examination of the cells on the surface of the
spheroid revealed that many were necrotic in appearance.
Spheroid Cross-Section Examination With Apoptotic and
Proliferative Markers 
The PCNA Marker for Proliferating Cells. The spheroids
that were growing in the absence of GLA had a thin outer
rim of PCNA-positive cells and a mean count of 5%
PCNA positivity across the spheroid radius, excluding ar-
eas of central necrosis (Table 1). When exposed to con-
centrations of up to 100 !m GLA, the overall number of
PCNA-positive cells increased. Table 1 shows the mean
PCNA indices for each cell line when exposed to increas-
ing concentrations of GLA. The greatest increase in
PCNA staining was observed within the peripheral band
of cells. As the band of cells became larger there was a
corresponding decrease in the viability of the cells within
the center of the tumor mass (Fig. 4), where few PCNA-
positive cells were observed. As the concentrations of
GLA were increased to more than 100 !M, the PCNA-
positive peripheral band was seen to decrease in size. The
overall trend in PCNA positivity is shown in Fig. 5.
Use of TUNEL Staining to Detect Apoptotic Index. The
control TUNEL experiments showed a consistent apoptot-
H. S. Bell, et al.
992 J. Neurosurg. / Volume 91 / December, 1999
FIG. 3. Photomicrographs showing the effect of 0-!M (control,
a), 50-!M (b), and 500-!M (c) concentrations of GLA on U87
spheroids in culture 48 hours after implantation. There is a larger
proliferative band (P) and invading cell population (I) with 50 !M
GLA compared with the control. There is an absence of both invad-
ing and proliferative cell populations with 500-!M GLA. The size
of the spheroid mass (S) remains consistent at all three concentra-
tions.
TABLE 1
Comparison of the mean apoptotic indices demonstrated by
TUNEL labeling and morphological assessment, and the
mean PCNA indices for each of the glioma cell lines*
Indices (% of counted cells)
GLA TUNEL H&E PCNA
Cell Line Dose (!M) (8 spheroids) (4 spheroids) (4 spheroids)
C6 0 4.2 2.8 2.6
50 31.4 22.6 10.2
100 47.6 38.4 3.5
500 83.2 72.0 1.0
U87 0 5.8 4.0 4.8
50 24.6 15.8 11.1
100 39.3 30.2 6.1
500 90.2 60.8 0.6
U373 0 3.9 2.8 3.2
50 28.6 20.0 11.1
100 50.0 40.0 4.2
500 79.0 68.3 0.3
MOG-G-CCM 0 5.1 3.8 6.2
50 30.1 22.2 11.1
100 50.9 41.6 5.0
500 88.3 67.8 1.2
* Morphological assessment with hematoxylin and eosin (H&E)
staining.
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Figure 1.5 Spheroids have been Utilized by a Number of Fields:  
Spheroids have been used in a number of fields including cancer research, (top) angiogenic 
sprouting of endothelial cells, (middle) and artificial tenocytes with embedded tendon cells 
(bottom) 66,98,123. Despite the diverse applications the similarities of the micron level 
structures are apparent. 	    
seen when total invasion distance on Day 5 was compared
with that on Day 6 or beyond. The maximum total inva-
sion distance seen was 2100 ⇤m. No statistical differences
in the total invasion distance were seen among the four
different concentrations of collagen type I gel assessed
(data not shown).
The medium obtained from cultures of spheroids im-
planted in collagen gels contained significantly increased
levels of all three types of enzymatic activity (Fig. 3). The
medium obtained from cultures of spheroids on collagen
gel contained significantly more general proteolytic activ-
ity and collagen type I degrading activity than medium
obtained from cultures of spheroids grown on plastic.
Of all protease blockers tested (including blocking pep-
tide, PMSF, warfarin, IAA, and pepstatin) only 1,10 o-
phenanthroline and TIMP-2 significantly decreased C6
astrocytoma cell invasion in this model (Fig. 4). This in-
hibitory effect was also seen when these two inhibitors
were added during the invasive process (data not shown). 
Proliferation Indices During Invasion
A positive reaction against Ki-67 was seen in the major-
ity of cells in surface microregions of spheroids obtained
from spinner culture or cultured for 24 hours in wells con-
taining no collagen type I gel (Fig. 5). No significant dif-
ferences in labeling indices between surface microregions
of large- and medium-sized spheroids were seen (75.3 ⇥
1% compared with 73.2 ⇥ 1.8%). No significant alter-
ation in the labeling index of this surface microregion was
seen when spheroids were cultured in wells without gel
for 5 days (Fig. 5). The central microregions that histo-
logically demonstrated pyknotic nuclei and small regions
of necrosis always gave a negative response for Ki-67
staining. 
The implantati  of pheroids into the gel was associat-
ed with striking changes. There was a significant decrease
in the labeling indices of the spheroid surface, all invading
cells, and the leading edge of invading cells as compared
to control (Fig. 5). After 24 hours, individual cells invad-
ing the gel continued to express Ki-67 antigen; however,
at Day 5 approximately 90% of the leading edge of invad-
ing cells reacted negatively. The labeling index at Day
5 in this subpopulation was significantly lower than that
found for all invading cells. The reason appears to be
that small subpopulations of invading cells form groups of
proliferating cells some distance away from the main
spheroid mass. The high labeling index in these clusters
at Day 5 suggests that these cells are actively undergoing
proliferation and similar small clusters of proliferating
cells can be seen at the spheroid edge. 
Histologically, the central microregion of the spheroid
no longer appeared to contain pyknotic cells and necrotic
microregions were no longer visible on Day 5. Occa-
sionally Ki-67 staining of cells in the central microregion
of the spheroid was seen, indicating that these cells were
undergoing mitosis.
M. Tamaki, et al.
604 J. Neurosurg. / Volume 87 / October, 1997
FIG. 1. Photomicrographs showing a C6 spheroid and C6 astrocytoma cell invasion into collagen type I gel. A: The
C6 astrocytoma cell invasion from a small spheroid after 24 hours. Original magnification   88; bar = 100 ⇤m. B:
Some cells appear to display a bipolar morphology (straight arrow), whereas others are more rounded in appearance
(curved arrow). Original magnification   210; bar = 100 ⇤m.
FIG. 2. Graph displaying total invasion distance from C6 spher-
oids monitored for 12 days. Conditioned medium was replaced on
Days 3, 6, and 9. The maximum invasion distance was approxi-
mately 2100 ⇤m and the maximum daily invasion distance was
seen on Day 1. The majority of invasive activity was seen from
Day 1 through Day 5. Values represent the means ⇥ standard devi-
ations (SDs) for three experiments.
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level of spontaneous angiogenesis. Even in the presence of
20% serum, on average they only gave rise to few capillary
sprouts with less than 50 µm length over a 3-day period (Fig.
3A,B). This behavior reflected the low autocrine activity of
HUVE cells. HUVE cells were, however, readily responsive to
exogenous stimulation by angiogenic growth factors. Addition
of either FGF-2 or VEGF induced capillary sprouting of
HUVE cells (Fig. 3A,C,D). In contrast to the low spontaneous
angiogenic activity of HUVE cells, spheroids of BAE cells
gave rise to intense sprouting, resulting in the formation of up
to 300 µm long capillary-like structures within 3 days (Fig.
3E,F). In fact, even a reduction of serum concentrations to
2.0% did not significantly affect the high baseline angiogenic
activity of BAE cells (data not shown), indicating and
extending previous findings in different bioassays (Korff and
Augustin, 1998; Villaschi and Nicosia, 1993; Mignatti et al.,
1991) that BAE cells are strongly regulated by autocrine
activity. Addition of exoge ous FGF-2 or VEGF stimulated
capillary sprouting of BAE cells, albeit to a much lower degree
compared with HUVE cells (Fig. 3E,G,H). 
Capillary sprouting from gel-embedded EC
spheroids leads to directional outgrowth of
anastomosing capillaries 
When seeding EC spheroids at different densities in the
collagen gel, we observed that beyond a critical spheroid
density, capillary sprouts originating from the spheroids gave
rise to complex anastomosing capillary-like networks (Fig.
2A). This observati n prompted u  to study systematically
directional sprouting in hr e-dimensional collagen gels and
the mechanisms that are responsible for this directionality. 
Upon seeding of EC spheroids into collagen gels, capillary
sprouts grow radially in all three dimensions (Fig. 4A,B). After
about 2 ay  in t e gel, some sprouts change their direction to
grow towards a n ighboring spheroid if this s heroid is in close
proximity. Analysis of a large number of gel-embedded
spheroids indicated that endothelial cell sprouts can sense
directionality in collagen gels over a distance of approximately
600-800 µm (Fig. 4C-E). Eventually, as the distance between
different capillary sprouts becomes smaller, several sprouts
align to span the gel between the two neighboring spheroids
(Fig. 4F). The directionality effect was identified as a specific
phenomenon of collagen matrices, since no signs of directional
capillary sprouting were observed in fibrin gels (data not
shown). 
Outgrowing capillary sprouts exert tractional forces
on the extracellular matrix
When spheroid-derived sprouts invade the collagen, they exert
tractional forces onto the gel. These tractional forces are
responsible for the shrinkage effect frequently observed when
cells are embedded in floating collagen gels (Vernon and Sage,
1996; Gullberg et al., 1990; Harris et al., 1981). In the present
study, we used nonfloating collagen gels that were solidly
anchored in their tissue culture well. N vertheless, regional
differences in tractional forces could be identified when
observing neighboring spheroids over several days. Fig. 4A
shows two collagen gel-embedded neighboring spheroids
approximately 1.6 mm apart. After 5 days in the collagen gel
and extensive directional sprouting, the centers of the two
spheroids were only approximately 1.2 mm apart, indicating
that the two spheroids have moved 25% closer together. 
Based on this observation, we analyzed the fibrillar structure
of the collagen gels that contained capillary-like structures.
T. Korff and H. G. Augustin
Fig. 2. Lumenized capillary sprouts originating from collagen gel-
embedded spheroids of BAE cells. Gel-embedded spheroids give rise
to radially outgrowing capillary sprouts. Outgrowing sprouts of
neighboring spheroids grow directionally towards each other to
establish networks of anastomosing capillary-like structures, as
shown by phase-contrast microscopic analysis of three adjacent
spheroids (A). Cross sections of gels with sprouts originating from
EC spheroids show capillary-like structures of varying size with
lining endothelial cells that form a true lumen throughout the gel.
The morphological appearance of these capillary sprouts ranges from
very small vessels lined by few EC (B-C) to larger structures lined by
numerous EC that form a bigger lumen (D-E). Depending on the
plain of section, sprouting EC originating from lumenized capillary
sprouts can be identified (D, arrow). Integration of EC into the lining
monocellular surface layer stabilizes the cells. Cells that are not
integrated into the monolayer become apoptotic (E, arrows). Bars,
500 µm (A); 20 µm (B-E).
A
stages included increases in COL1A2, COL3A1, SCX, TNMD and SOX9.
In comparison to 2D cultures, late stage 3D cultures demonstrated
modest benefits in terms of COL1A2, COL3A1 and TNMD expression,
with similar levels of SOX9 being observed. These observations
therefore go someway to supporting the concept of culturing
tenocytes under 3D conditions in the presence of TGF-b and IGF-1
in order to enhance and maintain a tendon like genotype.
With regards to tenogenic gene expression, the most pro-
nounced effects were observed in TDM-II, where IGF-1 had been
replaced by insulin and L-ascorbic acid 2-phosphate. Regardless of
which system was used, cultivation in TDM-II resulted in marked
increases in the expression of all tenogenic gene markers in late
stage cultures. Furthermore, in comparison to 2D cultures, TC-
microtissue spheroids examined at d y 6 de onstrat d signifi-
cantly enhanced expression levels of COL3A1, SCX and TNMD, with a
noticeable decrease in the expression of the chondrogenic marker
SOX9, and a complete absence of COL2A1. Moreover, not only were
the expression levels of tenogenic markers maintained in this
medium, ut were also in some cases enhanced at the later stages.
Clearly therefore, the combination of TGF-b1, insulin and ascorbic
acid appears to represent a novel supplement f r th purpose of
enhancing and maintaining a tendon-like genotype in 3D te ocyte
cultures, without indu ing chondrocyte-associated gene xpres-
sion. It should be noted however, that SOX9 expression was
increased by both TDM-I and TDM-II treatments in 2D and 3D
culture systems. The transcription factor SOX9 is recognized as
playing a pivotal role in regulating chondrocyte differentiation and
as such, is considered to be a reliable marker of chondrogenesis
[44]. Therefore, its upregulation in tenocyte cultures in response to
TDM-I or TDM-II could imply alterations in tenocyte differentiation
towards a more chondrogenic-like state. Certainly, over expression
of SOX9 in cultured tenocytes has been shown to result in decreases
in the expression levels SCX and TNMD and increas s in COL2A1
[45]. Moreover, forced expres io of SOX9 in chick tendon tissue
can lead to ectopic cartilage formation [45]. Howev r, despite our
observations that SOX9 expression levels were significantly
levat d in 2D and 3D tenocyt cultures treat d wi h either TDM-I
or TDM-II, the expression levels of SCX and TNMD, where expressed,
did not decre se. Mor importantly, COL2A1 xpression remained
below detection levels at all time points, regardless of treatment
regime. It therefore seems unlikely that the addition of TDM-I or
TDM-II had any profound influence on the chondrogenic status of
the equine tenocytes used in the current study. By comparison,
tenogenic markers were noticeably absent in 3D cultures treated
with TGFb-1 alone and expression levels of SOX9 remained signif-
icantly elevated, thereby indicating media supplemented solely
with TGFb-1 to be unsuitable for supporting the tenogenic differ-
entiation status of equine tenocytes in 3D microtissue spheroids.
In accordance with these findings, we could demonstrate that
collagen type I was also increased at the protein level in TC-
microtissue spheroids cultured in the presence of TDM-II.
Furthermore, when assessing protein lysates for the presence of
TNMD, we detected a additio al, high molecu ar weight protein
not observ TC-microtissue sph roids reated with growth
medium alone. It is unclear as to why TNMD was de ected in
tenocyt cultures treated with growth medium at ll, as qRT-PCR
analysis failed to detect any TNMD mRNA transcript. However, a
similar finding was also reported by Barsby et al. [46] in which
TNMD protein was observed in TGF-b-treated equine ESC cultures
in the absence of any detectable levels of TNMD mRNA. The cause
for such inconsistencies was accredited to disparities between
TNMD protein turnover and mRNA degradation rates. Therefore, it
seems plausible that the 250 kDa band observed in the current
study represents a high molecular weight variant of TNMD, being
Fig. 8. Outgrowth of equine tenocytes from TC-microtissue and their alignment in static 3D collagen constructs. TC-microtissues were p epared in hanging drops for 6 days in ither
GM or TDM-II and then embedded in 0.8% collagen matrix. Representative micrographs of hematoxylin and eosin stained paraffin wax sections of gel constructs at 2 (A, B), 4 (C, D)
and 5 (E, F) days after TC-microtissue seeding of GM (A, C, E) or TDM-II (B, D, F) treated cultures. Scale bar ¼ 100 mm. Inset, scale bar ¼ 20 mm. Arrow, orientation of collagen gels
based on their positioning in anchored silicon molds.
F. Theiss et al. / Biomaterials 69 (2015) 99e109 107
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Figure 1.6 The Vascularized Spheroid: 
The combination of EC and cancer spheroids has lead to a fully vascularized spheroid. 
Fibroblasts in the stroma stabilize vasculature formation. Evidence of interaction is 
apparent as cancer cells (green) can be seen within vasculature lumens (red) 119. 
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Chapter 2: Embedded Multicellular Spheroids as a Biomimetic 3D Cancer Model 
for Evaluating Drug and Drug-device Combinations  
  
Abstract 
Multicellular aggregates of cells, termed spheroids, are of interest for studying 
tumor behavior and for evaluating the response of pharmacologically active agents. 
Spheroids more faithfully reproduce the tumor macrostructure found in vivo compared to 
classical 2D monolayers. We present a method for embedding spheroids within collagen 
gels followed by quantitative and qualitative whole spheroid and single cell analyses 
enabling characterization over the length scales from molecular to macroscopic. Spheroid 
producing and embedding capabilities are demonstrated for U2OS and MDA-MB 231 
cell lines, of osteosarcoma and breast adenocarncinoma origin, respectively. Finally, 
using the MDA-MB 231 tumor model, the chemotherapeutic response between paclitaxel 
delivery as a bolus dose, as practiced in the clinic, is compared to delivery within an 
expansile nanoparticle. The expansile nanoparticle delivery route provides a superior 
outcome and the results mirror those observed in a murine xenograft model. These 
findings highlight the synergistic beneficial results that may arise from the use of a drug 
delivery system, and the need to evaluate both drug candidates and delivery systems in 
the research and pre-clinical screening phases of a new cancer therapy development 
program. 
  
	  	  
38 
Introduction 
Three dimensional (3D) in vitro cell culture models are being adopted as 
preclinical tools for studying tumor behavior and drug response 135. This paradigm shift is 
in response to a growing body of evidence that 3D systems promote greater in vivo-like 
cell behavior than their two-dimensional (2D) counterparts due to recreating more of the 
characteristic traits of the native tumor environment 2,136. As such, these models are 
proving more predictive than monolayer based systems. The majority of these 3D tumor 
cell models are prepared by either: a) growing cells on non-adherent surfaces or in 
suspension to induce cell clustering; b) seeding cells within a preformed polymer scaffold 
137–140 or c) embedding cells within a hydrogel to promote cell-cluster formation along 
with cell-matrix attachments 141. 
With regards to the latter technique, several polymer compositions including 
matrigel 9,142, collagen 143 , and hyaluronic acid 144 are being used to create 3D scaffolds 
in an effort to recreate the native extracellular matrix (ECM)-like environments in vitro 
5,145. These systems promote differential cell behavior when compared to 2D systems, but 
fail to reproduce the tumor macrostructure found in vivo 2,146. Clinical tumors usually 
consist of a singular structure with metabolically active cells at the surface and a necrotic 
core, while cell clusters in the 3D matrices are substantially smaller and numerous. Solid 
tumors also possess mass transport limitations stemming from decreased surface area-to-
volume ratios and longer diffusion lengths, which are not present in single cells or small 
cell clusters 11,146.  
To address these challenges, several methods of creating large cell clusters (>350 
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µm) are reported in the literature 19,147. These techniques eliminate or minimize the 
surface attachment sites for cells, forcing them to interact principally with each other, and 
include spinning flasks, hanging drops, and agarose coated plates. The resulting clusters, 
or spheroids, are of a similar size to small tumors. Unlike clinical tumors, they exist in an 
attachment-free microenvironment with very different mechanical and biochemical 
properties than the native ECM 148. This is an important caveat to their use, as matrix 
attachments via integrins and substrate mechanics play crucial roles in cell differentiation 
and survival 149. The interplay between the ECM and the tumor drastically affects drug 
response, epigenetic state, and metastasis in cancer 136,146. Therefore, there is a need for 
additional methods to prepare stable and reproducible models, which mimic the native 
tumor environment while being large enough for comparison to patient tumors. 
In order to simultaneously study and model key cellular parameters that regulate 
form and function including cell adhesion, cell-ECM interaction, biochemical state, 
mechanical properties, and tumor macrostructure, we present a scalable and reproducible 
method for embedding and manipulating cancer cell spheroids inside a 3D collagen gel. 
This spheroid-based model is easy to produce, cost-effective, quantitative, and high 
throughput with low setup time while providing opportunities to study proliferation, 
invasion, enzymatic activity, and antitumor agent activity for clinically relevant data 
acquisition. It builds upon previous spheroid and spheroid-collagen models, 
39,66,72,78,150,151 and enables individual spheroid manipulation along with whole spheroid 
and single cell analyses. Specifically, we hypothesize that a multicellular spheroid 
embedded within an ECM derived matrix of controllable stiffness capable of individual 
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manipulation, will allow quantitative and qualitative evaluation of the impact of 
chemotherapeutic agents across multiple cancer cell lines (Figure 2.1). In this study we 
characterize the effects of matrix stiffness, cell seeding number, cell type, and 
chemotherapeutic treatment on a collagen embedded spheroid. 
 
Materials and Methods 
Cell Culture 
Experiments were performed on the pediatric osteosarcoma cell line U2OS and/or breast 
adenocarcinoma cell line MDA-MB-231 (ATCC, Manassas, VA). Both cell lines express 
high levels of E-Cadherin, readily form spheroids, and are well characterized, including 
their protein expression and secretion profiles as well as have been extensively studied in 
cancer research applications 143,152. Cells were cultured in complete RPMI (U2OS) or 
DMEM (MDA-MB 231) media supplemented with 10% fetal calf serum and 1% 
penicillin-streptomycin solution (10,000 IU/mL penicillin; 10,000 µg/mL streptomycin). 
Cell cultures were maintained in 2D monolayers in a humidified incubator at 37°C, 5% 
C02.  
 
Spheroid Formation 
Cell aggregation was induced by growing cell suspensions on agarose-coated 96 well 
plates. Briefly, 1.5% (wt/vol) agarose solution was made by combining 0.15 g agarose 
(Sigma-Aldrich, St. Louis, MO) with 10 mL PBS. This solution was microwaved until 
agarose dissolution (~ 30s) and kept on a hot plate during the well coating process, to 
	  	  
41 
prevent premature gelation. To prepare the 96-well plate, 70 µL of the hot agarose 
solution was pipetted into each well and allowed to cool for 20 minutes. Separately, cell 
monolayers were detached from their culture flask via a standard typsinization protocol. 
Cells were counted and re-suspended in media to the desired concentration. Next, 100 µL 
of the cell suspension was added to each agarose-coated well. After 72 hours, the 
resulting cell aggregates were lifted via gentle pipetting and were immediately seeded 
into collagen gels as described below.   
 
Collagen Embedding 
Spheroids were transferred into an un-polymerized collagen gel following a published 
procedure 143. High Density Rat Tail Type I collagen (BD Biosciences) was diluted to 10 
mg/mL in 0.02 N acetic acid and combined 1:1 with a buffer solution (100 mM HEPES 
in 2x PBS, pH 7.3). This mixture was further diluted with PBS to the experimental 
collagen concentration (2–5 mg/mL). This solution self-polymerizes into a gel after 1 
hour at 37 °C. Tumor cell spheroids were added to 100uL of unpolymerized collagen 
solution in each well of a 96 well plate. After 1 hour, 200 uL of media or media with drug 
was added on top of the gel. This media was removed and replaced every 24 hours.  
 
Tracking Spheroid Growth 
After collagen embedding, spheroids were imaged every 24 hours for the duration of the 
experiment. Images were acquired on a DMI600B microscope (Leica, Solms, Germany) 
with an ImagEM EM-CCD Camera (Hamamatsu Photonics, Hamamatsu, Japan) in a 
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spinning disc confocal setup (Yokogawa, Tokyo, Japan). Imaging was done using Micro-
Manager 1.4 Software (http://www.micro-manager.org). Resulting images were analyzed 
with ImageJ software to measure spheroid diameter.  
 
Disaggregation of Spheroids for Assessment of Metabolic Activity 
MDA-MB 231 spheroids were transferred into collagen (4 mg/mL) for 24 hours prior to 
disaggregation by collagenase I treatment (2.38 mg/mL) (Life Technologies, Carlsbad, 
CA) in Hank’s Buffered Salt Solution at 37°C for one hour. Disaggregated cells from 
both spheroids and monolayer culture were seeded for 12 hours in 96 well plates. Cell 
viability was assessed via the MTS cell proliferation assay (Sigma, St. Louis, MO). 
Metabolic activity was calculated as the percentage of the positive control absorbance at 
490 nm. 
 
Live/Dead Staining 
MDA-MB-231 spheroids were stained with Calcein AM and Eithidium homodimer-1 
(Molecular Probes, Eugene, OR), for live and dead cells, respectively 72 hours after 
transferring to collagen (4 mg/mL).  Spheroids were either imaged as previously 
described with the addition of laser excitation of the sample at 488 and 561 nm or 
disaggregated for fluorescence-activated cell sorting (FACS). In addition to spheroids, 
MDA-MB 231 monolayers were stained for use as live and dead (after treatment with 
70% methanol) controls. Cells were fixed with 4% formaldehyde prior to FACS with 
appropriate filters.  Data was analyzed with FlowJo (Tree Star, Ashland, OR). Control 
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samples were gated for live and dead populations, and then applied to the spheroid 
sample to calculate a percent alive and dead. 
 
Nucleic Acid Extraction 
Nucleic acid was extracted from fully embedded spheroid samples using the Trizol 
Reagent without additional purification or disaggregation (Life Technologies, Carlsbad, 
CA). Subsequent RNA concentration was then measured with a NanoDrop Lite (Thermo 
Scientific, Wilmington, DE). Ten MDA-MB 231 spheroids (20,000 cells each) yielded 
4.735 µg RNA. 
 
Nanoparticle Preparation 
Paclitaxel-loaded expansile nanoparticles (Pax-eNP) were prepared as previously 
described 153. Briefly an oil-in-water mini-emulsion technique was used to polymerize 
monomer (5-methyl-2-(2,4,6-trimethoxyphenyl)-1,3-dioxan-5-yl)methyl methacrylate 
with crosslinker , 1,4-phenylene bis(2-methylacrylate) and the addition of (5% wt/wt) 
paclitaxel (MP Biomedicals, Solon OH). A non-loaded fluorescently labeled eNP was 
made in a similar manner using a covalently incorporated rhodamine co-monomer. 
 Paclitaxel was selected for study because of its clinical use in the treatment of metastatic 
breast cancer and other solid tumor malignancies. The mechanism of action is through 
binding and subsequent stabilization of microtubules which prevents dynamic 
reorganization 154. Due to insolubility the compound is clinically dissolved in Cremophor 
El  (1:1 solution of ethanol and polyoxyethylated castor oil) for in vivo administration.  
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Spheroid Treatment with Different Drug Delivery Methods 
MDA-MB 231 spheroids were made with 20,000 cells and subsequently embedded in 
collagen gels (4 mg/mL) for 24 hours. Spheroids were exposed to either 100 ng/mL or 
1000 ng/mL paclitaxel delivered via bolus dose (paclitaxel cremophor/ethanol) in the 
media or via Pax-eNP. In both cases, cells were incubated with the drug treatment for 24 
hours with monitoring of spheroid size over the following week. An analogous 
experiment was performed with fluorescently labeled eNPs, and the spheroid was imaged 
after treatment for 24 hours upon excitation at 561 nm. 
 
Results 
Spheroid Size is Linearly Dependent on Cell Seeding Number 
To demonstrate the scalability and reproducibility of spheroid formation, we investigated 
the dependency of cell seeding number on subsequent spheroid diameter. Figure 2.2 
shows the resulting trend-line for both the U2OS and MDA-MB-231 cell lines. The 
results demonstrate the fidelity and reproducibility of our method. In both cases, the data 
was fit to a power-law (R2 >0.98) with very small sample-to-sample error (<3% in U2OS 
cells and <5% in MDA-MB-231 cells). The horizontal error bars represent the cell 
counting errors arising from using a standard hemocytometer, which is estimated at less 
than 10%. The results indicate that homogenous samples are reproducibly prepared and 
that spheroid size can be precisely controlled.  	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Collagen Gel Properties Affect Spheroid Growth 
Embedding spheroids inside a matrix represents an important step forward in in vitro 
cancer research; however the matrix must be tunable to reflect the highly variable 
properties of the in vivo ECMs. Our chosen scaffold, type 1 collagen gels, can be 
prepared with different collagen content to directly control the pore size, attachment 
ligand density, and mechanical properties of the gels 51. We therefore investigated the 
effect of changing the collagen gel content surrounding the embedded spheroids by 
seeding spheroids in collagen gels with collagen content ranging from 2–5 mg/mL. These 
gels possess linear elastic moduli that vary over an order of magnitude, (~10–200 kPa) 
enabling us to expose the spheroids to a wide range of mechanical environments 155,156. 
Figures 2.3 and 2.4 show the line and contour plot of both U2OS and MDA-MB-231 
spheroid growth, respectively, over 72 hours in different collagen gels. In figures 3 and 4, 
the X-axis in the top figure represents time and the legend entries represent different gel 
collagen densities. In figures 2.3b and 2.4b, the colored XY-plane represents the spheroid 
size under those conditions. The spectrum, from red to purple indicates increasing 
spheroid diameter. In general, U2OS spheroids showed a standard deviation in diameter 
of 3–5% while the MDA-MB 231 spheroids showed slightly higher error of 
approximately 6–8%. By three days, there was a significant difference in the size of 
spheroids within the different collagen gels. In U2OS cells, spheroids grow the largest in 
4 mg/mL collagen gels while MDA-MB 231 cells exhibit optimal growth in 2mg/mL 
gels.  
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Tumor Like Characteristics 
For live/dead staining, the Ethidium homodimer-1 fluorescence was used to indicate a 
compromised cell membrane with subsequent binding to nucleic acids and Calcein AM 
staining demonstrated metabolically active cells. After 72 hours of growth within 
collagen, this live/dead staining revealed a pattern of metabolic activity cells surrounding 
a core of dead cells.  Figure 2.5 demonstrates a spheroid with a metabolically active ring 
of cells on the periphery combined with non-viable cell within the core. To quantitatively 
look at cell death, the same dyes were utilized via FACs. The population of disaggregated 
spheroids had 85.50±4.23% live cells and 14.50 ±4.23% dead cells. 
Next, the metabolic activity of spheroids embedded within collagen for 24 hours 
was assessed after being disaggregated and seeded in a monolayer. To account for cell 
growth during spheroid formation, cells were counted after disaggregation. After 96 
hours, spheroids seeded with 20,000 cells had grown to 60,125 ± 8,819 cells (n=4). 
Figure 2.6 shows a comparison of MTS metabolic activity of cells grown in a spheroid 
compared to cells grown solely in a monolayer. The cells from the spheroid exhibited a 
significantly lower metabolic activity (p<<0.05) being comparable to only 30,000 cells 
grown in a monolayer. 
 
Spheroid Response to Different Drug Delivery Methods 
We treated MDA-MB 231 spheroids with paclitaxel delivered either as a bolus or within 
expansile nanoparticles (eNPs) 153,157. Expansile nanoparticles are designed to directly 
transport the encapsulated drug into the cell using macropinocytosis, where pH-mediated 
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drug release occurs in the endosome 158. Figure 2.7 shows that eNPs have fully penetrated 
the spheroid within 24 hours (eNPs are labeled red). As shown in Figure 2.8, both 
treatments showed a statistically significant (p < 0.05) spheroid size reduction when 
compared to control samples. Interestingly, the decrease in spheroid size in response to 
paclitaxel treatment was similar for both the low and high dose (100 ng/mL versus 1000 
ng/mL) for a given delivery method, however, Pax-eNP resulted in significantly greater 
size reduction in spheroid diameter as compared to treatment with bolus paclitaxel. 
  
Discussion 
Over the last two decades, the identification of new anticancer agents for clinical 
evaluation has relied on the successful completion of in vitro cell toxicity assays, tumor 
bearing small animal models, and large animal biodistribution/toxicity studies. Animals 
do provide a physiological model for evaluating drug efficacy and toxicity, but are 
expensive, labor intensive, and low throughput. In contrast, the rapid and high throughput 
in vitro models used to analyze cellular and multicellular responses are based on 2D 
monolayers, and possess a number of limitations including artificial and unrealistic 
mechanical environments with a lack of ECM, tumor macrostructure, and diffusion 
gradients 146. The results obtained with these 2D monolayer models, therefore, do not 
always reflect or predict in vivo performance. Thus, 3D cell spheroid models are being 
used to more accurately represent the native tumor environment (and mirror the findings 
observed in preclinical tumor bearing animals or patients). Building on the successes of 
previous 3D spheroids, 39,63,66,72,78,151 we extend this methodology and report a scalable 
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method for preparation of single spheroids of controllable size incorporated into collagen 
gels as a tumor model.  
 Using cell lines derived from two different human carcinomas (osteosarcoma, 
U2OS, and adenocarcinoma, MDA-MB 231, cell lines), we demonstrate the ability to 
accurately control the size of multicellular spheroids based on cell seeding. Osteosarcoma 
and adenocarcinoma spheroids are prepared ranging from ≈ 115 to 395 and 200 to 875 
µm in diameter, respectively, based on initial cell seeding number (Figure 2.2). As the 
spheroid is embedded in collagen, a suitable matrix is provided for cell ingrowth and 
interaction with cells, as observed in vivo. The collagen gel also provides a means to 
further control tumor-matrix interactions through alteration of the mechanical properties 
of the collagen gel. Osteosarcoma and adenocarcinoma spheroids perform strikingly 
differently in collagen gels varying in modulus from ~10 to 200 kPa. As shown in 
Figures 2.3 and 2.4, U2OS and MDA-MB 231 spheroids with diameters ranging from ≈ 
335 to 395 and 550 to 800 µm, respectively are observed based on the mechanical 
properties of the collagen gels.  The largest osteosarcoma spheroids are present in the 
stiffest gel while the largest adenocarcinoma spheroids are found in the softer gel. The 
preference of bone and breast cancer cells for stiffer and softer gels, respectively, 
indicates an optimal mechanical environment for these cells, and is consistent with other 
reports 159,160.  
 Optical imaging of the single intact spheroid enables evaluation of spheroid 
shape, morphology, and surface characteristics as well as analysis after histological or 
classical optical live/dead stains. Figure 2.5 shows an optical image of a MDA-MB-231 
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spheroid after Calcein AM/ Ethidium homodimer-1 staining, highlighting the 
metabolically active ring of cells on the periphery along with the non-viable cells located 
within the core. Observation of these tumor hallmarks reflects the metabolic and 
proliferative gradients present in this model 2,142. The combination of decreased metabolic 
gradients and growth reduces overall metabolic activity in 3D-culture compared to its 
2D-monolayer counterpart 2,142. To further assess this effect in our model, collagen 
embedded MDA-MB 231 spheroids were disaggregated, seeded in a monolayer, and 
analyzed for metabolic activity. As shown in Figure 2.6, cells from the spheroid display a 
relatively lower MTS activity value compared to those grown in 2D.  In fact, 60,000 
spheroid-grown cells exhibit the activity of approximately 30,000 cells grown in a 
monolayer. However, an MTS focuses solely on metabolic level of live cells. To 
ascertain the population of dead cells, FACs was used, confirming that after 3 days in 
collagen a portion (14.50 ±4.23%) of the spheroid is dead. This latter result documents 
that our spheroid model is amenable to both single cell analyses (e.g., cell uptake, 
metabolic activity, DNA studies), and whole spheroid experiments. Furthermore, nucleic 
acid extraction allows insights into global changes in genetic expression. 
A key feature of this system is the ability to investigate the complexity of cancer 
treatment by providing a model solid tumor as opposed to conducting studies on a 
monolayer. One potential application of this model is as a tool for evaluating drug 
delivery devices and quantifying their impact on tumor size. Penetration through the 
collagen and the spheroid as well as cellular uptake must be carefully considered when 
treating large cell masses, but these delivery challenges do not arise in monolayer cell 
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cultures. We therefore hypothesized that similar to tumors in vivo, where 
pharmacological kinetics play an important role in drug efficacy, collagen embedded 
spheroids will show a differential drug response when the delivery method is varied. For 
these studies, we compare paclitaxel delivery as a bolus dose, as is practiced in the clinic, 
versus loaded within an expansile nanoparticle 153. The expansile nanoparticle is designed 
to localize to the tumor and once inside the tumor cell or ECM where the pH is mildly 
acidic (pH = 5.5–6.5), the particle will expand or swell to release the paclitaxel resulting 
in focused localized tumor delivery. 
A striking difference in efficacy, as measured by spheroid growth inhibition, is 
observed between these two paclitaxel delivery methods (Figure 2.8). Although bolus 
delivery does slow growth, the effect is significantly more pronounced with delivery via 
expansile nanoparticles. A second set of experiments examines the uptake of rhodamine 
labeled eNPs in the spheroid using confocal microscopy and shows the eNPs dispersed 
throughout the spheroid after diffusing through the collagen and into the spheroid (Figure 
2.7). This result is similar to eNPs in vivo, where eNPs are present within the tumor and 
release drug locally over time as opposed to the bolus delivery of paclitaxel where the 
tumor is only transiently exposed to drug. Interestingly, when these two paclitaxel 
delivery modes are tested in the same cell line in a 2D monolayer there is no difference in 
response between bolus and eNP delivered paclitaxel 157. In contrast, our findings using 
the 3D spheroids mirror the results obtained using an established human triple negative 
breast cancer fat-pad tumor mouse model 157. A bolus dose of paclitaxel results in a small 
reduction in tumor size, while the Pax-eNP treatment significantly reduces tumor growth 
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after 6 weeks (p<0.05).  The spheroid model better replicates the observed in vivo 
response of the two different paclitaxel delivery methods. These results speak to the 
importance of evaluating drug candidates along with the method of delivery as 
synergistic beneficial results may arise from the combination. 
Several studies report that cells grown in monolayer are more sensitive to 
radiation exposure when compared to in vivo tumors 161,162. Equal doses of radiation to a 
malignant cell line had a greater effect when the tumor cells were grown as a monolayer 
rather than in a murine tumor model 161. This discrepancy is attributed to increased 
cellular robustness due to cell-cell proximity, paracrine signaling, and a hypoxic core 
148,163. Spheroids with 3D cell contacts and hypoxic regions, which reduce the presence of 
reactive oxygen species, are more predictive of in vivo radiation response than are cell 
monolayer models 148,163–165. When a human melanoma line was treated with radiation 
both as in vitro spheroids and in vivo murine tumors, delay in cell growth within 
spheroids correlated with survival with in vivo tumors 164. In addition to radiation, 
spheroids are being used as a testing model for multiple experimental treatments such as 
photodynamic therapy 166, gene therapy 167, and radioimmunotherapy 168. These examples 
highlight the need for and relevance of using 3D spheroids for assessing existing 
treatment methods and exploring novels treatments. Although a step forward, these 
spheroid-based experiments disregard contributions from the extracellular matrix. The 
collagen embedded spheroid model would further increase the relevance of the spheroid 
system as a tool for therapy assessment and discovery. 
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Conclusion 
While no tumor model fully recreates the in vivo system, the presented model 
combines the favorable attributes of a spheroid structure with an extracellular matrix. It 
builds on the successes of previous 3D spheroid models and extends the methodology for 
preparation of single spheroids of controllable size incorporated into a collagen gel as a 
tumor model. The key features of this tumor model are: 1) a multicellular spheroid of 
controllable size; 2) a collagen based ECM structure surrounding the spheroid; and 3) a 
spheroid with a metabolically active outer layer and necrotic core. Our technique remains 
easily scalable for high throughput applications and the combination of whole spheroid 
techniques with single cell analysis allows in-depth investigations into basic cancer cell 
behavior from the tissue to single molecule scales. Using this tumor model, we observed 
performance differences in terms of chemotherapeutic response based on the mode of 
paclitaxel delivery, which unlike the monolayer experiments mirrored the results 
obtained in an in vivo animal study. In summary, the 3D biomimetic culture platform 
described here will facilitate the study of basic cancer cell behavior, the evaluation of 
new anticancer agents, the role of drug delivery devices in optimizing the anti-tumoral 
response, and the development of simulation software for data modeling and predictions.  
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Figures 
 
Figure 2.1. Creation of Embedded Spheroids:  
Spheroid formation is encouraged by placing a suspension of cells (red) in media (pink) on 
agarose (yellow) coated wells. After 72 hours, a spheroid is formed, and then transferred 
into a collagen gel. 	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Figure 2.2. Controllable Spheroid Size:  
Spheroid size can be controlled by varying cell seeding number. Sizing based on cell seeding 
number was demonstrated with both bone (top) and breast (bottom) cancer cells. 	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Figure 2.3. U2OS Spheroid Growth in Collagen:  
Bone cancer spheroids grown in collagen gels with varying mechanical properties 
demonstrated the most growth in 3–4 mg/mL, growing less in both stiffer and weaker gels. 
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Figure 2.4. MDA-MB 231 Spheroid Growth in Collagen:  
Breast cancer spheroids grown in collagen gels with varying mechanical properties 
demonstrated the most growth in the weakest collagen gels. 
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Figure 2.5. Pattern of Metabolic Activity:  
A spheroid in collagen was stained with a calcein-based stain (green) to show metabolically 
active cells and an ethidium based stain (red) to demonstrate cells with a compromised 
membrane. The red staining on the interior indicates a mostly dead core, whereas the green 
cells shows a metabolically active outer ring of cells. The inset quantitatively demonstrates 
that 85.5% of the spheroid is alive after 3 days via FACS. 
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Figure 2.6. Metabolic Activity of Spheroids: 
Disaggregated spheroids were plated in a monolayer and the metabolic activity was 
compared to cells grown only in a monolayer. Although there were approximately 60,000 
cells, the overall metabolic level is comparable to 30,000 cells. 	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Figure 2.7. Nanoparticle Penetration:  
Within 24 hours fluorescently labeled nanoparticles were able to fully penetrate a 20,000 
cell MDA-MB 231 spheroid. Scale bar is 100 µm. 	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Figure 2.8. Spheroid Treatment with Nanoparticles:  
Paclitaxel, a chemotherapeutic drug was delivered via bolus dose or nanoparticles for 24 
hours before the treatment was removed. The nanoparticle delivery method was the most 
effective at reducing spheroid size. 
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Chapter 3: Mimicking the Tumor Microenvironment to Regulate Macrophage 
Phenotype Using an Embedded Spheroid 
 
Abstract 
 Tumor associated macrophages are critical as stromal components intimately 
involved with the progression, invasion, and metastasis of cancer cells. To address the 
need for an in vitro system that mimics the clinical observations of TAM localizations 
and subsequent functional performance, a tumor cell/macrophage spheroid model is 
described. The central component is a triple negative breast cancer spheroid embedded in 
a three-dimensional collagen gel. Macrophages are incorporated in two different ways. 
The first is a heterospheroid, a spheroid containing both tumor cells and macrophages. 
The heterospheroid mimics the population of TAMs infiltrated into the tumor mass, thus 
being exposed to hypoxia and metabolic gradients. In the second approach, macrophages 
are diffusely seeded in the collagen surrounding the spheroid, thus modeling TAMs in the 
cancer stroma. The inclusion of macrophages as a heterospheroid changes the metabolic 
profile, indicative of synergistic growth. In contrast, macrophages diffusely seeded in the 
collagen bear the same profile regardless of the presence of a tumor cell spheroid. The 
macrophages in the heterospheroid secrete EGF, a cytokine critical to tumor/macrophage 
co-migration, and an EGF inhibitor decreases the metabolic activity of the 
heterospheroid, which is not observed in the other systems. Lastly the increased secretion 
of IL-10 indicates that the heterospheroid macrophages follow an M2/TAM 
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differentiation pathway. In summary, the heterospheroid model and accompanying 3D 
collagen microenvironment promote TAM-like characteristics. 
 
Introduction 
A malignant tumor is more than a single, mutated cell population replicating 
without regard to the otherwise healthy tissue, within which it resides. Rather the 
surrounding stroma maintains a dynamic relationship with the tumor, through which it is 
intimately involved in cancer initiation, growth and progression. Furthermore the stroma 
exerts such influence that a normal architecture can suppress a malignant phenotype 9 and 
an activated stroma can promote neoplastic progression 169. Both acellular and cellular 
components of stroma can influence tumor progression 51.    
 Cellular components of the tumor stroma include fibroblasts, myofibroblasts, 
endothelia cells, pericytes, macrophages and a variety of inflammatory cells 170. Tumor 
Associated Macrophages (TAMs) are a macrophage subset that drew early interest due to 
histological observations of macrophage tumor infiltration 171,172. Macrophage content in 
human tumors varies from 50–80%, with one study in breast cancer quantifying 
infiltration as 490 and 343 macrophages/mm2 for medullary carcinomas and ductal 
carcinomas, respectfully 173,174. Clinically, high TAM infiltration indicates worse overall 
and relapse-free survival, emphasizing their potential importance in cancer progression 
and prognosis 175,176. TAMs, classified as M2, or alternatively activated macrophage, are 
generally associated with tissue repair and remodeling, tumor promotion, metastasis and 
immunoregulation 177,178. This is in contrast to M1 or classically activated macrophages 
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that destroy intracellular pathogens by triggering a proinflammatory response 179. 
 Given the critical role TAMs play, the development of in vitro models, which 
recapitulate the interplay between TAMs and tumor cells, is of significant basic and 
clinical interest. TAMs and tumor cells have been modeled in vitro using monolayer co-
culture 180 and supernatant transfer 181, both of which are sufficient for tumor cells to 
promote M2 pathway activation associated with TAMs. However a monolayer is 
insufficient in providing the environmental cues that define a tumor microenvironment, 
and is unable to replicate the 3D localization of macrophages with respect to the tumor. 
Pollard et al., identified three distinct TAM populations present in both human and 
murine tumors: 1) in the surrounding stroma; 2) in necrotic, hypoxic areas of the tumor 
and; 3) aligned with the abluminal side of vessels 182. These locational differences within 
the tumor demonstrate the necessity for TAM/tumor models that reflect clinical 
observations. 
 Spheroids offer an opportunity to mimic elements of an in vivo tumor, such as the 
multicellular nature, metabolic gradients, and inclusion of stromal factors such as ECM 
and secondary cell types. Spheroids were first prepared in the 1970s based upon the 
premise of forming a multicellular structure by denying cells an attachment site 11,19. 
Multiple cell types have been incorporated in a spheroid during formation to form a 
heterospheroid 34. However, the most common method of producing a macrophage 
spheroid model consists of a spheroid in an agarose coated well exposed to macrophages 
in the surrounding media. Using this configuration, individual spheroids of breast tumor 
cells or cancer associated fibroblasts were used to characterize infiltration of 
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macrophages into a tumor versus its fibroblast rich stroma 27. A novel drug delivery 
method was explored when TAMs laden with gold nanoshells infiltrated a spheroid, and 
were then irradiated to treat adjacent tumor cells 28. In another study, the role of TAMs in 
tumor angiogenesis was characterized by implanting an infiltrated spheroid into a murine 
model and documenting subsequent TAM-driven angiogenesis 29. TAM inclusion led to 
release of VEGF with increased angiogenesis demonstrated by increased vessel number 
and length. The use of these models has provided key insights into TAM biology. Unlike 
the previous model, Hauptman, et al., incorporated an extracellular matrix (ECM) mimic 
by first preparing a spheroid on an agarose coated well and then transferring it onto a 
layer of collagen. They studied the complexity of tumor/macrophage interaction by 
demonstrating that the inclusion of different macrophage phenotypes had significant 
affects on colon cancer cell migration and proliferation 30. For example, one subtype, 
similar to macrophages found in central tumor regions, increased proliferation, but 
prevented migration. Although an improvement, the model does not provide a fully 3D 
ECM, where macrophages populate and migrate along the fibrillar collagen surrounding a 
tumor 183,184. Furthermore, these models do not enable the concurrent study of two 
different TAM subpopulations such as that found in the surrounding stroma or necrotic 
regions. Herein, we describe two different tumor cell/macrophage spheroid models that 
includes: 1) a triple negative post metastatic breast cancer cell line; 2) a spheroid 
recapitulating tumor macrostructure; 3) collagen as an ECM mimic; 4) incorporation of 
macrophages within the spheroid or in the surrounding microenvironment; 5) 
measurement methods that include whole spheroid and single cell analyses; and 6) 
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EGF/EGFR interactions as an example of an important cytokine-based interaction 
between the macrophages and breast cancer cells.  
 
Materials and Methods 
Cell Culture 
MDA-MB 231, a human post metastatic adenocarcinoma cell line, and RAW 264.7, a 
murine Abelson leukemia transformed macrophage/monocyte line were cultured in 
Dulbecco’s Modified Eagle Media supplemented with fetal bovine serum (10%) and 
penicillin/streptomycin (1%, 10,000 IU/mL penicillin; 10,000 mg/mL streptomycin). Cell 
lines were kept at 37°C in a humidified chamber with 5% CO2. Propagation was 
performed as recommended by ATCC, with macrophages requiring mechanical removal.  
 
Spheroid Formation 
The method for spheroid formation follows previously published method, with the 
addition of 2.5% Matrigel and centrifugation at 1,000 g for 10 minutes as seen in the 
literature as shown in Figure 3.1b 22,185. RAW 264.7 cells were added to agarose-coated 
plates in quantities ranging from 500–5,000 with 10,000 MDA-MB 231 cells to create a 
heterospheroid. The diffuse model was formed by inclusion of the RAW 264.7 cells 
during the spheroid embedding, which was otherwise performed as previously described 
185. 	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Imaging 
Brightfield images of spheroids on agarose were captured using an Olympus IX70 
microscope with an Insight camera. Resulting images were analyzed on ImageJ. DIC 
images were acquired on a DMI600B microscope (Leica, Solms, Germany) with an 
ImagEM EM-CCD Camera (Hamamatsu Photonics, Hamamatsu, Japan) in a spinning 
disc confocal setup (Yokogawa, Tokyo, Japan). Fluorescent imaging was performed with 
the addition of lasers, with excitations of 488 and 561 nm. Imaging was done using 
Micro-Manager 1.4 Software (http://www.micro-manager.org). Assembling of frames 
into a single image was done in Matlab. 
 
Fluorescently Stained Heterospheroids 
MDA-MB 231 cells and RAW 264.7 cells were stained with green and red cell trackers, 
(Molecular Probes, Eugene, OR) respectively at 20 µM prior to spheroid formation. 
Heterospheroids were imaged after 72 hours on agarose, with 25 µm intervals.  
 
Oxygen Presence 
In order to gauge metabolic rate, oxoplates measured the partial pressure of oxygen in the 
media. Measurements were obtained in 96 well oxoplates (PreSens Precision Sensing, 
Regensburg, Germany) using a SpectraMax M5 plate reader (Molecular Devices, 
Sunnyvale, United States). Data was analyzed according to manufacturer’s instructions. 	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Protein Secretion 
Media samples were taken at 24-hour intervals. Secreted proteins were detected on the 
last day of culture via a Mouse EGF ELISA (Sigma-Aldrich, St. Louis, United States) or 
Mouse Interleukin-10 (IL-10) ELISA (Abcam, Cambridge, United States).  
 
Inhibitor Treatment 
Systems were treated with EGFR inhibitor Tyrphostin AG 1478 (Sigma-Aldrich, St. 
Louis, United States) in literature-observed concentrations ranging from 0.2–200 nM for 
24 hours prior to oxoplate measurement 186 
 
Results 
Macrophage Incorporation into the Spheroid Model  
The impact of macrophage inclusion on tumor spheroids was studied in the collagen 
embedded breast cancer (MDA-MB 231) spheroid model in two different ways as shown 
in Figure 3.1. Collagen embedding was performed as previously described, where a 
spheroid was prepared on an agarose-coated well before transferring into a 4 mg/mL 
collagen gel 185. The first method of macrophage incorporation was a two cell type 
“heterospheroid,” and the second was by diffusely incorporating macrophages into the 
collagen gel surrounding a spheroid of breast cancer cells. In order to form a spheroid 
containing tumor cells and macrophages, a combination of macrophages, breast cancer 
cells and matrigel was added to the agarose-coated wells. The resulting heterospheroid 
contained two cell types in different specified ratios. When 10,000 breast cancer cells 
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were included with a varied number of macrophages (500–5,0000), the corresponding 
spheroid diameter increased as shown in Figure 3.2. For the entire range of macrophage 
concentrations used (500–5,000 cells), spheroid formation occurred. The diameter 
appeared to plateau at ~800 µm when 2,500 or 5,000 macrophages were added. Higher 
macrophage concentrations were not explored as increasing macrophage content 
decreases the robustness of the spheroid. To investigate localization by cell type prior to 
collagen embedding, cells were labeled with a fluorescent cell tracker before spheroid 
formation. The resulting image of a spheroid combining 1,000 macrophages and 10,000 
breast cancer cells showed a homogeneous mixture of cell types throughout the structure 
(Figure 3.2E). Throughout the text, heterospheroids will be described by the number in 
thousands of the tumor cells followed by macrophages, such that 10T5M refers to a 
heterospheroid with 10,000 tumor cells and 5,000 macrophages. 
The second design of a tumor cell/macrophage spheroid model has the 
macrophages embedded in the collagen gel surrounding the cancer cell spheroid. A 
10,000 tumor cell spheroid surrounded by 5,000 macrophages diffusely seeded in the 
collagen will be referred to as 10Td5M. A tumor cell only model, consisting of a breast 
cancer spheroid embedded in collagen (10T), and a macrophage only model with 5,000 
diffusely seeded macrophages in a collagen gel (d5M) served as controls. Images of all 
four systems with 5,000 macrophages are shown in Figure 3.3. The cell systems were 
grown for eight days in collagen. The method of macrophage incorporation significantly 
affected overall morphology. Diffusely seeded macrophages formed multiple, large 
clusters which achieved diameters greater than 100 µm by day eight, in the presence or 
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absence of the tumor spheroid. In contrast, heterospheroids grew as a singular, large, 
dense structure containing both cell types.  
 
Synergistic Growth in Spheroid Systems 
Oxoplates, which monitor the presence of oxygen consumptions by cells, were used to 
observe the overall metabolism of the four cell systems. Figure 3.4. shows the relative 
oxygen presence for the four different component models using 5,000 macrophages 
and/or 10,000 tumor cells: tumor spheroid alone, a heterospheroid, diffusely seeded 
macrophages with a tumor cell spheroid, and a macrophage only model. Oxygen presence 
declined steadily from 100% to approximately 30% at the end of eight days in the 
spheroid (10T) model. The oxygen consumption of a spheroid surrounded by 
macrophages (10Td5M) followed the trajectory of a single spheroid until day three when 
consumption increased and oxygen presence rapidly decreased. This pattern was mirrored 
by diffusely embedded macrophages (d5M), where the abrupt decrease in oxygen 
presence occurred between day four and five. However, the heterospheroid (10T5M) 
rapidly consumed oxygen from the beginning, starting at an initial oxygen presence of 
only 79% and continuing with an exponential decay. The slope decreased over time, with 
all macrophage containing samples reaching the same relative oxygen presence by day 
seven and resulting in significantly lower levels than with tumor spheroids alone.  The 
highest rate of oxygen consumption is found with the heterospheroids suggesting a 
synergistic growth pattern of the two composite cell types.  
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Cytokine Based Interactions 
Media samples from each of these four cellular systems were assessed for the presence of 
the known macrophage-derived mouse epidermal growth factor (EGF). Figure 3.5a 
shows EGF levels detected by ELISA on samples taken on day eight (n=4). The 10T5M 
heterospheroids secreted the highest concentration of EGF (50.0 ± 10.7 pg/mL). This was 
statistically higher than EGF in all other models (p<0.005). The 10Td5M model secreted 
12.8±3.9 pg/mL EGF versus 4.7±2.9 pg/mL by diffusely seeded macrophages (d5M), 
which was statistically lower than the 10Td5M (p<0.05). Secretion levels for 10T were 
the lowest at 2.8±6.0 pg/mL, which was not statistically different from levels secreted by 
d5M.  
We hypothesized that increased cellular activity and secretion of growth factors, 
for example, may be responsible for the increased oxygen consumption demonstrated by 
10T5M heterospheroids. Therefore we determined EGF expression for each of the four 
systems, and then treated with an specific inhibitor in order to block interactions between 
the macrophage-derived EGF and the EGF receptor (EGFR) known to be upregulated on 
carcinoma cells, including MDA-MB 231 187,188. Specifically, the 10T5M heterospheroids 
were treated with increasing doses (0.2–200 nM) of the EGFR inhibitor Tyrphostin AG 
1478. Figure 3.5b shows that, within 24 hours of EGFR inhibition, 10T5M responded to 
concentrations from 0.2–200nM in a dose dependent manner. The lowest dose at 0.2 nM 
did not afford a statistically different response from untreated heterospheroids. However, 
the relative oxygen presence significantly increased from 50.4±4.5% for 10T5M without 
inhibition to 72.3±9.8% at the maximum EGFR inhibitor dose of 200 nM (p<0.005). 
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Treatment of 10T5M with 200 nM Tyrphostin decreased the oxygen presence to levels 
previously noted for heterospheroids with only 1,000 macrophages (75.1±6.9%). No 
concentration dependent response was observed when analogous models 10Td5M and 
10M were treated with Tyrphostin AG1478 as shown in Figure 3.6. 
 
Macrophages Skewed to M2 Differentiation Subset  
IL-10 secretion has previously been shown to be a marker for M2 differentiation in 
TAMs using RAW 264.7 macrophages 189.  Figure 3.7 demonstrates that macrophages 
diffusely cultured in collagen secrete less IL-10 in the presence of a spheroid (d5M 
versus 10Td5M: 5.4±1.7 pg/mL versus 1.8±0.8 pg/mL, respectively). Heterospheroid 
culture afforded the largest production of IL-10 at 30.2±18.3 pg/mL, which was 
statistically higher than all other values (p<0.05). As expected, the spheroid alone (10T) 
had negligible IL-10 secretion at 0.3±4.0 pg/mL. 
 
Discussion 
As our knowledge of cancer biology grows, it has become clear that monolayer 
systems are too simplistic to adequately model the complexity of the interactions between 
a growing tumor and the surrounding stroma. The cellular and extracellular stromal 
components known to support the progression and growth of a tumor are potential targets 
for novel treatments. Given the role of tumor-associated macrophages in the migration, 
invasion, and metastatic potential of carcinoma, TAMs are of particular interest. Recent 
evidence that TAMs can modulate the efficacy of existing therapeutics and drive 
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reparative mechanisms post-treatment has increased the interest in TAM manipulation 
190. For example, skewing TAM polarization away from the pro-angiogenic/immune-
suppressive M2 phenotype toward a tumor-inhibiting phenotype 191 or the use of a novel 
chemotherapeutic, trabectedin, that selectively kills monocytes, including TAMs 192 are 
both being investigated as novel treatments. However, the lack of in vitro models of 
tumor cell/TAM interactions limits progress given the significant challenges of using 
animal models for these studies 191–193. In vivo growth of human tumor xenografts 
requires the use of immunocompromised animal models, which by default will have 
altered immune responses, and thus tumor microenvironments 194. Therefore there is a 
critical need for the development of in vitro tumor models that can better study TAMs in 
the context of the tumor macrostructure and physiologically relevant TAM/tumor co-
localization.  
In response to this need, we explored two tumor cell/TAM spheroid models 
mimicking solid tumor within a surrounding collagen gel as a model ECM. Due to the 
effect of tumor microenvironment on TAM function, macrophages were incorporated and 
studied in these models in two different ways – either diffusely within the surrounding 
collagen (10Td5M) or within the tumor spheroid forming a heterospheroid (10T5M). 
Incorporation of macrophages within a heterospheroid mimics the population clinically 
found in necrotic and hypoxic areas by Pollard and others 195,196. Interestingly, we have 
previously demonstrated that cell death and necrosis do occur at the center of tumor 
spheroids resembling those used in the current study 185. The second model investigates a 
tumor spheroid surrounded by a macrophage population diffusely seeded in the collagen 
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(10Td5M). This models the stromal population found in normoxic regions of breast 
cancer shown by Lewis et al. 196. Despite the same ratio of cells, these models respond 
differently, demonstrating the importance of localization, microenvironmental cues, cell 
clustering, and nearest neighbor effect. 
The differences in the macrophage microenvironment between the 10T5M and 
10Td5M models result in different metabolic profiles despite the same ratio of cell types 
(Figure 3.4). The growth profile is characterized by measured oxygen presence as this has 
been correlated to viability 197. The 10T5M heterospheroid exhibits an early decrease in 
oxygen presence unlike any of the other cell systems, suggesting that the 10T5M 
heterospheroid uniquely demonstrates synergistic growth between the two cell types – 
tumor and macrophage, similar to that demonstrated in vivo. In contrast, the oxygen 
presence with the 10Td5M model resembles that of the d5M model, and, thus, is 
consistent with macrophage-driven growth rather than synergistic growth. The slightly 
decreased oxygen presence noted in 10Td5M compared to d5M alone is likely due to the 
addition of the tumor spheroid itself, which is not present in the macrophage only model. 
In contrast, despite plating the same number of cells, the 10T5M heterospheroid model 
has a significantly higher oxygen consumption (i.e. lower oxygen presence) than the 
10Td5M model, suggesting significantly greater cell growth and/or metabolism driven by 
synergistic interactions between the macrophages and breast cancer cells in the 
heterospheroid model.   
On a cellular level, TAMs follow an M2 or alternative activation pathway, which 
is generally associated with tissue repair and remodeling, tumor promotion, and 
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immunoregulation177. Interestingly, tumor cells can promote a pro-tumor activation 
pathway in macrophages through the secretion of cytokines (including CSF-1, CCL17 
and CCL22) and ECM components 177. In response, TAMs promote angiogenesis by 
secreting VEGF and COX-2 198, and induce co-migration of both tumor cells and TAMs 
with the secretion of epidermal growth factor (EGF) 199,200. The binding of EGF to the 
corresponding EGF receptor (EGFR) found to be over expressed in a number of cancers 
including breast cancer, stimulates the secretion of CSF-1, which further drives 
macrophages along the pro-tumor pathway in a positive feedback loop with nearby tumor 
cells 199,200. In our model, secretion of EGF was found to be minimal for single cell 
models, including macrophages alone, but was significantly increased in the mixed 
macrophage/tumor models. This was particularly true in the10T5M model where the 
heterospheroids produced more than four times the amount of EGF seen in the 10Td5M 
model. This increased EGF production observed in the heterospheroid is consistent with 
the positive feedback loop between tumor-associated macrophages and the tumor cells 
reported in the literature 199. Furthermore, blocking this interaction markedly decreased 
the overall metabolism in the heterospheroid systems but not the other tumor containing 
systems, confirming that the EGF/EGFR interaction is at least partly responsible for the 
early and sustained decrease in oxygen presence characteristic of heterospheroids (Figure 
3.4).  Previous in vitro TAM/tumor cell systems demonstrated that co-culture of TAM 
and tumor cells could induce EGF expression 199,200. However, the current manuscript 
demonstrates that co-culture alone is insufficient, and that EGF secretion is significantly 
increased in the interactive environment of a TAM/tumor cells heterospheroid.  
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IL-10 is a cytokine involved in various anti-inflammatory activities that is 
frequently upregulated in a number of cancers, including breast cancer, correlates with 
stage 201, and its production is associated with TAM conversion to an M2 activation 
pathway 202. Experimentally, the conversion of RAW 264.7 cells to an M2/TAM 
phenotype was confirmed by IL-10 secretion 189 and can be achieved by treatment with 
exogenous cytokines such as IL-4 203 or in response to nanoparticle surface chemistry 204. 
The high concentration of IL-10 produced by the heterospheroid system, indicates that 
the combination of the microenvironment, ECM mimic, and relatively close proximity of 
macrophages to cancer cells within the heterospheroid is sufficient for TAM conversion. 
Future work will focus on characterizing the microenvironment of the heterospheroid 
core versus the diffuse embedding of macrophages throughout the collagen. The 
macrostructure within tumor spheroids introduces the intrinsic triggers of hypoxia 205, 
decreased pH 206, and increased cell-cell contacts between macrophages and tumor cells, 
akin to those seen in vivo. Further elucidation of the microenvironmental cues in this 
model will lead to a greater understanding of TAM phenotype and function as it relates to 
tumor growth and metabolism. Improvements in the modeling of the tumor 
microenvironment will require the incorporation of additional relevant cell types, such as 
cancer-associated fibroblasts, which are also prominent in tumor stroma and have been 
implicated in the progression of disease. Secondly, other immune components exert an 
effect on TAM function and phenotype 207, such that even more cell types may be 
ultimately required to accurately reflect the significant complexity that exists within a 
growing tumor in vivo. 
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Conclusion 
We present four distinct iterations of a collagen embedded model: a spheroid 
composed of only tumor cells (10T), diffusely seeded macrophages (d5M), a spheroid 
diffusely surrounded by macrophages (10Td5M) and a macrophage/tumor cell 
heterospheroid (10T5M). The heterospheroids recapitulated EGF-based interactions, 
promoted tumor growth in a model dependent manner and secreted cytokines consistent 
with an M2 TAM polarization. The heterospheroid exposes macrophages to a 
microenvironment more consistent with that found within an in vivo tumor, thus reducing 
the need for exogenous agents that are often utilized to attain M2 polarization. The source 
of differentiating cues is limited to the accompanying breast tumor cells, and the 
multicellular macrostructure. However in the spheroid model, TAM differentiation is not 
solely achieved through the co-culturing of breast cancer and macrophage lines since the 
10Td5M model demonstrates significantly lower TAM conversion than 10T5M 
heterospheroids. Rather, it is the synergistic combination of co-culture and macrophage-
tumor proximity and interaction present within the heterospheroid that results in M2 
differentiation and the accompanying increases in oxygen consumption and metabolism. 
Therefore, we present new insights into understanding TAM/tumor cell interactions 
within the context of an activated tumor stroma and promote the use of in vitro 
heterospheroid and diffusely seeded systems as models of breast tumor infiltrated with 
TAMs for future discoveries in cancer biology, drug development, and delivery. 	    
	  	  
77 
Figures 
 
Figure 3.1 Macrophage Incorporation into Spheroid Model: 
Starting with an embedded spheroid model, the influence of macrophages (shown in green) 
was studied using four different component models (A). The first was a breast cancer 
spheroid (shown in red) embedded in a collagen gel (left). The second model consists of 
diffusely embedded macrophages within a collagen gel. The third model combines these 
with a spheroid surrounded by diffusely seeded macrophages within a collagen gel. The 
fourth model is a heterospheroid composed of both cell types. B) Heterospheroids are 
formed by including breast cancer cells and macrophages during spheroid formation on 
agarose in various ratios (bottom). 	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Figure 3.2 Heterospheroid Formation: 
Macrophages were incorporated during spheroid formation to form a heterospheroid with 
a defined number of macrophages. Images show spheroids with tumor cells and 0 (A), 1,000 
(B), or 5,000 (C) macrophages. D) Inclusion of a greater number of macrophages resulted in 
increased spheroid diameter. E) A stained image with tumor (green) and macrophage (red) 
cells demonstrate a homogeneous mixture throughout the spheroid. The scale bar is 100 µm 
for all images. 	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Figure 3.3 Collagen Embedded Models: 
 A spheroid composed of 10,000 tumor cells (10T) grows into collagen over eight days as a 
homogeneous structure. A heterospheroid with 10,000 tumor cells and 5,000 macrophages 
(10T5M) forms a large but uniform structure resembling 10T. Both systems containing 
diffusely embedded macrophage have large clusters of macrophages present by day eight, 
with spheroid growth in the 10dT5M model appearing uninterrupted. All scale bars are 500 
µm. 
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Figure 3.4 Synergistic Growth in Spheroid Systems:  
The presence of oxygen provides an indication of overall metabolic activity and cell growth 
rate. The method of macrophage incorporation results in starkly different oxygen 
consumption patterns. The heterospheroid demonstrates a faster decrease in oxygen 
presence compared to the diffuse model, suggesting a synergistic growth pattern due to the 
interactions of the two cell types within a heterospheroid model (n=6).  
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Figure 3.5 Cytokine Based Interaction of Macrophages and Tumor Cells: 
A) EGF concentration detected by ELISA is greatest in the heterospheroid system 
compared to any of the other systems (p<.005). B) Addition of an EGFR inhibitor at 
concentrations from 0.2–200 nM increased the oxygen presence in 10T5M systems by 
disrupting the EGF/EGFR interaction. The oxygen presence of untreated 10T5M is 
statistically different (p<0.005) from treatments of 200 nM. (* Indicates p<0.005.) 
	    
	  	  
82 
 
Figure 3.6 Cytokine Based Interaction of Macrophages and Tumor Cells:  
An EGFR inhibitor at concentrations from 0.2–200 nM had no effect on the oxygen 
presence in 10Td5M system (top) or 10T system (bottom). Thus indicating the lack of 
EGF/EGFR interaction within this system. 
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Figure 3.7 Heterospheroid Enhances TAM Conversion:  
Secretion of IL-10 indicates the alternative M2 activation pathway associated with TAMs. 
Heterospheroids generated the highest concentration of IL-10, statistically different from all 
other systems (p<0.05). 
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Chapter 4: Contributions of 3D Culture and Tumor Microenvironment to 
Chemoresistance in an Embedded Spheroid Model 
 
Abstract 
 A monolayer differs significantly from the multicellular nature and three-
dimensional growth demonstrated by a tumor. As a result of these disparities, cells in a 
monolayer are genetically different from their counterparts. In order to examine the effect 
of three-dimensional culture and tumor macrostructure on drug response, three models 
composed of a post-metastatic, triple negative breast cancer cell line were tested. The 
first is a traditional monolayer. The second consists of cells diffusely seeded within a 
collagen gel, thus a three-dimensional culture system. The third model contains a 
multicellular spheroid embedded within a collagen gel, thus incorporating both tumor 
macrostructure and a three-dimensional nature. Based on this premise, we examined how 
the models respond to two clinically relevant chemotherapeutics, paclitaxel and cisplatin. 
When treated with either drug, the viability of the monolayer fell below 20%, with more 
robust responses from the diffuse model of 30–40% viability. The spheroid model 
contains two distinct populations, a core, a dense aggregate of cells, and a periphery, cells 
that have grown into the surrounding collagen. The viability of the periphery after 
treatment is approximately 30%, which is not statistically different from the diffuse 
model, thus indicating their similar drug responses. Despite an effect against the 
periphery, the core demonstrates chemoresistance to both drugs, with an overall viability 
of 90%. After treatment with either drug, the core is removed from the system and 
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embedded into new collagen. Cisplatin retards its subsequent growth, while paclitaxel did 
not have a significant effect on growth. An enrichment of cancer stem cells in the core 
could be responsible for the chemoresistance observed. This research demonstrates the 
dual response of the spheroid model to treatment with a chemotherapeutic agent. Loosely 
aggregated cells, invading the collagen are susceptible to treatment, in contrast to the 
dense, tightly packed core population. 
 
Introduction 
The growth of immortalized cell lines on polystyrene is an inadequate substitute 
for the complex microenvironment of a growing tumor. Before addressing the changes in 
cell behavior imposed by tumor macrostructure, growth in a 2D environment is 
fundamentally different from a 3D environment. The planar nature of 2D growth 
geometrically constrains the cells, allowing contact with only an artificially imposed 
basal lateral attachment, resulting in extreme spreading 1. The downstream effects of 
monolayer growth result in genetic upregulation in the following categories: 1) cell 
cycling, 2) metabolism and 3) turnover of macromolecules, thus enabling enhanced 
proliferation 2. For applications in drug delivery and discovery, the change from 2D to 3D 
dramatically increases the robustness of a cell to toxicity in both normal and cancerous 
contexts, underscoring the need for 3D models 5,6. 
The differences between a monolayer and a tumor microenvironment are greater 
than dimensional. In vivo tumors feature differences in oxygenation, perfusion, pH and 
metabolic states that separate it from normal tissue 12. These cues are induced by the 
	  	  
86 
macrostructure of the tumor, and its surrounding environment. An avascular tumor or 
small micrometastasis (under approximately 2 mm3) is characterized by gradients of 
metabolites, catabolites, and oxygenation, with proliferation at the edges and necrosis at 
the core 11. These gradients form around leaky, tortuous vasculature resulting in a 
heterogeneous environment. Therefore, malignant cells are faced with a spectrum of 
environments. One extreme is a quiescent or apoptotic cell exposed to hypoxia, cell/cell 
contacts, low pH and low perfusion that exist within a central location far from a 
capillary. The other extreme is a well-perfused, metabolically active cell, with high 
cell/ECM contacts more representative of cells at the periphery of a tumor or next to a 
capillary. The result is a heterogeneous range of metabolic states where actively cycling 
cells are adjacent to capillaries whereas distant cells become quiescent and possible 
necrotic or apoptotic.  
From a clinical standpoint, these two differences of three-dimensional culture and 
the heterogeneous microenvironment could significantly impact the efficacy of 
chemotherapeutics. As already noted, the difference between 2D and 3D is enough to 
decrease the toxicity of chemotherapeutics. However, detailing the effect of tumor 
microenvironment onto 3D cultures requires more physiologically relevant models. In 
1971 Sutherland, et al. presented spheroids as a model of nodular carcinoma. Spheroids 
were formed upon the premise of denying cells external attachment sites besides other 
cells to form a large multicellular aggregate. Rotator flasks formed spheroids of 150–370 
µm in diameter when cultured for up to 24 days 19. Upon reaching a diameter of 200 µm, 
necrosis developed in the center of the aggregate, with division at the outer edges. In 
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addition to spinner flasks, multiple fabrications strategies are routinely used, all of which 
are based on denied attachment sites such as hanging drop or liquid overlay. The further 
incorporation of collagen as an ECM mimic around such spheroids has led to the 
identification of two subpopulations within spheroid models of glioma 68,76–78 and 
melanoma 65. The first population referred to as spheroid core is dominated by cell-cell 
contacts, while the periphery or invasive population contains more cell-ECM contacts. 
Although spheroids have been extensively used for evaluating chemotherapy efficacy, 
most correlate efficacy with invasion into the collagen 78,92,93. While this approach is 
useful for drugs whose mechanism of action is based on high metabolic activity, for 
drugs that target non-metabolic pathways, such as forming crosslinks in DNA, the impact 
on invasion might be minimal. Furthermore, focusing solely on migration into collagen, 
might bias results towards metabolically active periphery/invasive population and ignore 
effects on the cells located within the core. Research by An, et al. sought to separate the 
effect of suberoylanilide hydroxamic acid on invasion versus viability 95. Collagen 
embedded glioma spheroids visually demonstrated a decrease in invasion in both invasive 
and core populations after treatment. A viability assay after treatment detected a small 
decrease in cell number indicating an invasion-independent effect. However, viability 
assays were performed on the entire spheroid, which cannot identify differences in 
sensitivity between the core and periphery populations. The only separation of two 
populations observed in the literature was performed by Gole, et al. when studying 
mechanisms of invasion 79. Increased cathepsin B activity was observed in the invading 
population despite no upregulation at the mRNA (via rt-PCR) or proteomic level 
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(measured in cell extracts by ELISA). Therefore the aim of this study is two fold. First, to 
elucidate the differences in drug response when comparing four populations in three 
different models: 1) a monolayer; 2) a 3D culture model; 3) the invasive or periphery of a 
spheroid model and 4) the core population of a spheroid model as shown in Figure 4.1. 
The second aim of this study is to evaluate the efficacy of two chemotherapy drugs with 
invasion-independent metrics.  
 
Materials and Methods 
Cell Culture 
MDA-MB 231, a post metastatic human adenocarcinoma cell line was cultured in 
Dulbecco’s Modified Eagle Media supplemented with fetal bovine serum (10%) and 
penicillin/streptomycin (1%, 10,000 IU/mL penicillin; 10,000 mg/mL streptomycin). Cell 
lines were kept at 37 °C, in a humidified chamber with 5% CO2.  
 
Three Dimensional Cancer Models 
The method for spheroid formation followed a previously published method, with the 
addition of 2.5% Matrigel and centrifugation at 1,000 g for 10 minutes as seen in the 
literature 22,185. Spheroid embedding in 4 mg/mL collagen was performed as previously 
described 185. The diffuse model utilized the same collagen matrix, with cells 
incorporated after harvesting from a monolayer.  	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Drug Treatment 
Models were treated with either paclitaxel in Cremophor EL or cisplatin (cis-
diamminedichloroplatinum (II)). Drug treatment started 24 hours after transfer into 
collagen for duration of 72 hours. Unless stated, paclitaxel concentration was 10 ng/mL 
and cisplatin concentration was 1.5 µg/mL (5 µM). Models were monitored for a total of 
eight days. Fluorescent imaging of paclitaxel was performed with a fluorescent analog, 
Paclitaxel Oregon Green® 488 (Molecular Probes, Eugene, United States). 
 
Oxygen Consumption 
In order to gauge metabolic rate, oxoplates (PreSens- Precision Sensing, Regensburg, 
Germany) measured the partial pressure of oxygen in the media. Embedded models were 
prepared as previously described in 96 well oxoplates. Measurements were conducted 
using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, United States) with 
ex/em of 540/590 and 540/650.  
 
Imaging 
DIC images were acquired on a DMI600B microscope (Leica, Solms, Germany) with an 
ImagEM EM-CCD Camera (Hamamatsu Photonics, Hamamatsu, Japan) in a spinning 
disc confocal setup (Yokogawa, Tokyo, Japan). Fluorescent imaging was performed with 
a 488 nm laser. Imaging was done using Micro-Manager 1.4 Software 
(http://www.micro-manager.org). Assembling of frames into a single image was done in 
Matlab. 
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Cell Viability Assay 
Models are treated with chemotherapeutics as previously described. On the eighth day 
both collagen embedded models are disaggregated in a solution of 1 mg/mL collagenase 
at 37 °C for 45 minutes. The core population of the embedded spheroid model was 
removed and separately disaggregated in trypsin for 20 minutes at 37 °C. The resulting 
suspension of cells was seeded in a monolayer for 12 hours. The monolayer samples 
remain seeded during disaggregation of the three dimensional models. Cell viability was 
tested using a colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) cell proliferation assay with 
absorbance read at 490 nm (Sigma, St. Louis, MO). Cell viability in each well was 
calculated as a percentage of the untreated control of each model. 
 
Proliferation Assay  
The spheroid model was treated with chemotherapeutics as previously described. On the 
eighth day, the surrounding collagen and periphery cells were removed via 
disaggregation in collagenase. The spheroid core was seeded into 4 mg/mL collagen on 
oxoplates or tissue culture plates for imaging, and monitored for eight days without 
additional drug treatment. 
 
ALDEFLUOR Assay 
The cancer stem cell (CSC) populations were quantified using the commercially available 
ALDEFLUOR Stem Cell Identification and Isolation Kit (Stem Cell Technologies) and a 
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BD LSRII flow cytometer (BD Biosciences).  Briefly, cells were incubated in 
ALDEFLUOR assay buffer containing ALDH substrate (1 µM per 5 x 105 cells) for 30 
minutes at 37 ºC.  For each experiment, a sample of cells was stained under identical 
conditions with 50 mM of diethylaminobenzaldehyde (DEAB), a specific inhibitor of 
aldehyde dehydrogenase (ALDH), as a negative control.  The sorting gates were 
established using propidium iodide-stained cells for viability, and CSCs were identified 
as the subpopulation of cells with high ALDH-activity.  
 
Mammosphere Assay 
Cells were harvested from the aforementioned experimental conditions and subjected to a 
mammosphere assay.  Here, cells were grown on 6-well ultra-low adherence plates 
(Corning) at a clonal density of 2x103 cells per well in mammosphere growth media; 
which is composed of serum-free mammary epithelial growth media (MEGM, Lonza) 
supplemented with B27 minus Vitamin A (Invitrogen), 20 ng/mL EGF and 20 ng/mL 
bFGF (BD Biosciences), and 4 µg/mL heparin (Sigma). Half volumes of media were 
added every 3 days.  After 10 days, brightfield images were acquired using a Leica 
DMI600B microscope with a spinning disc confocal setup.  Mammospheres, identified as 
multicellular aggregates larger than 70 µm in diameter, were identified and counted using 
ImageJ and a custom-written MATLAB code.  	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Results 
Model Response to Paclitaxel and Cisplatin 
We evaluated the efficacy of two cytotoxic agents on all four of our populations. The first 
drug, paclitaxel prevents microtubule disassembly during cell division, and it is a first 
line chemotherapeutic agent used in treatment of breast cancer 154. The second drug, 
cisplatin acts via binding and subsequent crosslinking of DNA, and is used to treat 
testicular, bladder, ovarian, colorectal, breast, and lung cancer 208,209. After 72 hours of 
drug exposure followed by 72 hours of additional culture, the models were imaged 
(Figure 4.2). When treated with paclitaxel, cell ingrowth into the collagen matrix was 
significantly decreased, resulting in a small, dense structure. Treatment with cisplatin 
decreased cell ingrowth into the collagen to a lesser extent, with small populations of 
cells visible far into the collagen, as with the untreated control. The dense spheroid core 
demonstrated no morphological differences after treatment. Both monolayer and diffuse 
culture presented with an increase, in rounded, spherical cells after treatment with either 
drug, in contrast to the elongated morphology of untreated cells. The monolayer IC50 
was assessed using a colorimetric metabolic assay, and was calculated as 4.81 ng/mL and 
0.987 µg/mL for paclitaxel and cisplatin, respectively as shown in Figure 4.3. However 
these methods do not allow direct comparison between the different models.  
The drug response was quantified across models by disaggregating, seeding in 
monolayer culture for 12 hours, and then using a colorimetric metabolic assay. 
Disaggregation allowed separation of two populations from the spheroid as shown in 
Figure 3a. The “core” refers to the dense compact region, which appears as a black circle 
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in DIC images and the  “periphery” refers to the halo of cells around the core. In order to 
separately characterize both populations in the spheroid, collagenase was first used to 
disaggregate the collagen, leaving a suspension of periphery cells and the intact core. The 
core was then removed and subsequently treated with trypsin for disaggregation. When 
assessed separately, the periphery responded to paclitaxel and cisplatin, with viabilities of 
34 and 29%, respectively. In contrast, the core demonstrated a robust response with 
viabilities of 91 and 97% to paclitaxel and cisplatin, respectively. The monolayers had a 
similar response with 17 and 16% viability for paclitaxel and cisplatin, respectively. 
Paclitaxel and cisplatin had decreased efficacy of 30 and 36%, respectively in the diffuse 
model compared to the monolayer model. The experimental results demonstrate the 
chemoresistance of the core, compared to the other populations. 
The previous experiment elucidates the effect of drugs on the viability of the 
models, but does not provide information on the proliferative ability. Therefore, the core 
population was removed after 72 hours of exposure to drug and then 72 hours of 
additional culture, and embedded into a new collagen gel shown in Figure 4.5a. The core 
was cultured for an additional eight days, before oxygen presence was measured as a 
metric for growth. Spheroids previously treated with paclitaxel demonstrated a slight 
increase in oxygen presence when compared to untreated control spheroids shown in 
Figure 4.5b. However, this difference was not significant (p> 0.05) indicating that earlier 
treatment with paclitaxel was not sufficient to prevent subsequent growth. Spheroids 
previously treated with cisplatin had significantly higher oxygen presence (p<0.01), 
signifying that cisplatin is more effective at retarding proliferation. All models 
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demonstrated growth as confirmed by DIC images shown in Figure 4.5C. To test for drug 
penetration, models were treated with a fluorescent analog of paclitaxel and imaged on 
the last day of culture (Figure 4.6). The presence in the monolayer (4.6A) and spheroid, 
including the core (4.6B) indicate that drug is able to penetrate within the dense spheroid 
core.  
 
Quantifying Cancer Stem Cells in Different Populations 
The CSC content was compared between the “core” and the “periphery.” CSCs were 
identified and quantified using two separate techniques: 1) Aldefluor assay which 
identifies cell with high levels of the enzyme aldehyde dehydrogenase via a fluorescent 
substrate 210 and 2) mammosphere assay where cancer stem cell’s self-renewal properties 
were exploited to form clusters 211.  
In our studies, the Aldefluor assay revealed that cancer stem cells were 
preferentially located in the core versus the periphery at an approximate ratio of 2:1 
(Figure 4.7, left). In the second method, the disaggregated cells from the spheroid were 
seeded in small concentrations on low-adherence plates and cultured for 14 days. Cell 
clusters indicate CSC presence as they can divide in non-adherent conditions. A ratio of 
5.5:1 clusters demonstrates an increase in cancer stem cells in the core vs. the periphery 
(Figure 4.7, right).  
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Discussion 
Here we present three separate models to quantitatively assess how 3D culture 
and tumor microenvironment impact the reduced chemosensitivity often observed in 3D 
systems 5. The diffuse system offers 3D cell/ECM interactions, but lacks the multicellular 
structures reminiscent of tumor macrostructure. The embedded spheroid model combines 
3D culture with macrostructure that leads to two discrete populations, a dense core 
highlighting cell/cell interactions and a periphery of cells that are invading into the 
surrounding collagen. After treatment with two clinically relevant drugs with different 
mechanisms of action, the viability of a given population is similar with both drugs. This 
suggests that the viability trends observed are independent of the mechanism of action. 
 Paclitaxel and cisplatin consistently demonstrate the highest efficacy in the 
monolayer. The move to the diffuse three-dimensional system decreases the toxicity of 
both paclitaxel and cisplatin, so viability is approximately twice that of the treated 
monolayer. Interestingly, for both cisplatin and paclitaxel, the quantitative response of the 
spheroid periphery was similar to that of the three dimensional culture. This suggests that 
the drug response of cells in the periphery is primarily modulated by three-dimensional 
culture, not tumor macrostructure. Viability results indicate that paclitaxel and cisplatin 
have similar toxicities on cells in the periphery. However, paclitaxel is more effective 
than cisplatin at reducing invasion into the collagen matrix as observed in Figure 4.2. 
This apparent difference in efficacy is skewed by the mechanism of the drug. Paclitaxel is 
most effective against actively dividing cells, which will be at the periphery of the 
spheroid, and reduced at the core 11. Therefore, if invasion is the metric it will appear 
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more effective. However, disaggregation and quantitative assessment reveal very similar 
efficacies of the two drugs against the spheroid periphery. Furthermore, it appears that for 
invading populations, the effect of the tumor microenvironment on chemosensitivity is 
minimal.  
 The spheroid core is unlike the spheroid periphery, diffuse system and monolayer 
population tested, in that it exhibits a robust response to both drugs. This chemoresistance 
is not observed in the spheroid periphery or diffuse system, suggesting that it is primarily 
due to the imposed macrostructure rather than three-dimensional culture. When the 
ability of the cells to divide after treatment was tested, both cores retained the ability to 
proliferate. However, cisplatin is more effective at retarding growth. This could be due to 
its metabolic independent mechanism of action, where it causes crosslinks in the DNA. 
Therefore while neither paclitaxel nor cisplatin causes a dramatic decrease in viability of 
the cells in the core, cisplatin is more effective at reducing proliferation. The difference in 
drug response between the spheroid core and periphery demonstrates the need to 
separately evaluate these dual populations. Whole system measurements or imaging 
simply do not reveal their disparities. In order to elucidate the lack of chemosensitivity, 
the core and periphery were separated to test for cancer stem cell content. We 
hypothesized that the cancer stem cells might be responsible for the decreased toxicity of 
chemotherapeutics observed in the spheroid core.  
 Cancer stem cells (CSCs) are stem-like cells, which are linked to 
chemoresistance, recurrence, metastasis, and progression 212. CSCs initiate and maintain 
tumors, due to their ability to both self-renew and form differentiated populations 213.  
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This theory is supported by the tumor initiating capabilities of CSCs where they form 
tumors at a much higher rate than their non-CSC counterparts. CSCs can be identified via 
surface marker expression 214, proliferation under non-adherent conditions 215, dye-
retention assays 216 and the presence of the enzyme aldehyde dehydrogenase 210. In 
addition to being found in clinical samples from a number of tumors including breast, 
small percentages have been identified in several immortalized monolayer cells lines, 
including MDA-MB 231 217, which is consistent with our results.  
The fields of spheroids and CSCs have intersected due to the CSC’s ability to 
divide in non-adherent conditions in which spheroids are formed. One way to both enrich 
and test for CSC presence is the mammosphere assay, where cells form small spheroids 
in suspension culture 218,219. However due to slow proliferation rates of CSCs, and small 
starting number for generation of large spheroids this has proven both challenging and 
time consuming 96. One use of spheroid culture has been to maintain the stemness seen in 
vivo by culturing human samples of liver, colorectal and ductal tumors in spheroids to 
prevent the loss of stemness associated with monolayer culture 220. Similarly, non-
embedded spheroids were used to enrich a stem-like population in a canine mammary 
line 221. Fan, et al. also demonstrated an order of magnitude increase in CSCs by 
maintaining a colorectal line in spheroid culture 222. They also linked the spheroid-
forming population to an increase in the IC-50 the drug 5-fluoracil when compared to the 
adherent monolayer population 222. However, none of these studies utilized embedded 
spheroids, which remove the possibility of the two populations. To our knowledge, this is 
the first manuscript to demonstrate preferential localization and enrichment of CSCs in 
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the core versus periphery. In addition our data suggest that the chemoresistance of the 
core, could be partially due to the presence of CSCs. This supports existing data linking 
CSCs to both cisplatin 223 and paclitaxel 224resistance. 
 
Conclusion 
 As our knowledge of how 3D culture and tumor microenvironment impacts 
chemotherapeutic response grows, the monolayer seems too simplistic to serve as an 
adequate model. In this manuscript we compare the response of four different populations 
of cells to cisplatin and paclitaxel to explore the contributions of 3D culture and tumor 
environment to chemoresistance. The change in viability of the populations is similar 
with both drugs, perhaps indicating that this response is mechanism independent. 
Compared to the 3D systems, the monolayer demonstrates the largest decrease in 
viability after treatment with chemotherapeutics. In contrast, the 3D diffuse system 
responds similarly to the periphery, indicating that tumor microenvironment contributions 
to the periphery are minimal. By separating the two populations for evaluation, the 
chemoresistance of the core is apparent. This robust response to chemotherapeutics could 
be due to an enrichment of CSCs within the core. Contributions to chemoresistance are 
dominated by tumor microenvironment with lesser contributions from 3D culture. It 
should be noted that the core retains the ability to proliferate after treatment. However 
unlike paclitaxel, cisplatin can significantly decrease proliferation. This suggests that 
chemotherapeutics that do not target metabolically active populations may be more 
effective at reducing proliferation of hypoxic, quiescent cells.  
	  	  
99 
The use of the two drugs validates the need for non-invasion based evaluations of 
drug efficacy for an embedded spheroid model. Although both drugs had similar effects 
on viability of spheroid populations, they had strikingly different invasion profiles. 
Therefore using invasion as a drug efficacy metric is limited due to the heavy bias by the 
drug’s mechanism of action. In conclusion we demonstrate the increased chemoresistance 
of the spheroid core population, potentially due to CSC presence, and a method for 
invasion-independent viability evaluation. 
 
Future Work  
Although a link between chemoresistance in the core and CSC presence has been 
presented, the CSCs have not been proven to be integral to the drug response observed. 
CSC presence should be assessed post treatment to demonstrate if they are truly resilient 
to treatment. However, even if a stemlike population remains, it does not prove they 
contribute to the chemoresistance of the entire core, just that they are not susceptible to 
the treatments used. CSCs are understood to be a small percentage of the tumor 
population; so the resilience of a small population might not have an effect on the overall 
viability demonstrated by our research. In order to elucidate their contribution to the 
population, a fully differentiated spheroid should be subjected to drug treatment. 
Thereby, demonstrating any change in drug sensitivity is due to the absence of CSCs.  
 Beyond the impact of CSCs on chemoresistance, the mechanism through which it 
acts requires further research. As with non-malignant stem cells, CSCs protect 
themselves through expression of transporters, namely the adenosine triphosphate-
	  	  
100 
binding cassette (ABC) transporters 225. These efflux pumps are purported to confer 
chemoresistance on the CSCs (Hirschmann, 2004). Therefore, the ABC expression within 
the CSCs, as well as the wider population of spheroid core and periphery will be 
quantified, to assess the role of efflux in response. To directly evaluate drug presence, the 
concentration of both drugs will be measured within both spheroid populations, and 
compared to the CSC population.  
 While we have presented the enrichment of the CSCs in the spheroid core, the 
entire core population could be predisposed to greater drug resistance due to 
environmental factors. The next step is to characterize the environmental cues that could 
enable this enhancement. Therefore, the physical factors that might distinguish the core 
from the periphery such as oxygen, pH, stiffness, and ECM structure will be 
characterized. This may reveal cues stimulating the core population that may act 
alternately or in concert with CSC population to increase the overall resilience of the 
core. 
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Figures 
 
 
Figure 4.1 Models for Drug Efficacy Evaluation: 
The MDA-MB 231 cells were used in three models. The left is a monolayer. The middle is a 
3D system with cells diffusely embedded in a collagen gel. The third model is a spheroid 
embedded in collagen with two discrete populations, a core (red) and periphery cells 
(purple). 	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Figure 4.2 Morphological Drug Response of Systems: 
The systems of MDA-MB 231 cells were imaged after 72-hour drug exposure followed by 
72-hour recovery. Following treatment, the monolayer experienced a decrease in overall cell 
number with an increase in large, rounded cells. When the diffuse 3D model was treated, 
morphological differences are subtle. However there appears to be an increase in large, 
rounded cells after treatment with either drug. Spheroids treated with paclitaxel 
experienced drastically reduced cell invasion into the collagen. Cisplatin treatment had a 
less dramatic effect on overall collagen invasion.   
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Figure 4.3 Monolayer Drug Response: 
The monolayer IC50 values for paclitaxel (top) and cisplatin (bottom) are 4.81 ng/mL and 
0.987 µg/mL, respectively.  	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Figure 4.4 Drug Efficacy in Different Populations: 
A) After treatment with collagenase the periphery population is disaggregated into a 
suspension. The core is then removed and disaggregated with trypsin (B). The core and 
periphery populations are disaggregated and then plated in a monolayer. The relative 
viability demonstrates the ability of the core to resist apoptosis after treatment with 
paclitaxel (B) or cisplatin (C). The monolayer is the most sensitive to treatment with either 
drug. The spheroid periphery and diffuse 3D system are more resistant than the monolayer 
to either drug, but less resistant than the core. 
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Figure 4.5 Spheroid Growth After Treatment:  
A) After treatment the core can be separated from the periphery and reseeded into 
collagen.  B) When reseeded into collagen after treatment, the growth of the core is retarded 
but not prevented by cisplatin (p<0.01). Paclitaxel treatment does not significantly decrease 
growth. C) All cores seeded into new collagen gels demonstrated some growth. All scale 
bars are 500 µm. 
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Figure 4.6 Paclitaxel Oregon Green Penetration: 
The presence of paclitaxel Oregon green in the monolayer and core indicates the decrease 
efficacy is not due to lack of availability.  	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Figure 4.7 Enrichment of CSCs in the Core:  
There is a higher percentage of CSCs in the core compared to the periphery as 
demonstrated by Aldefluor assay (left) and mammosphere assay (right). 
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Chapter 5: A Novel Method for Modeling Biopsy 
within an Embedded Spheroid Model 	  
Abstract 
 Tumors are described as a wound that does not heal due to the contributions of 
inflammation in cancer incidence and progression. To study the effect of a wound on a 
growing tumor, we developed a novel, facile, reproducible model for removing half of an 
embedded spheroid and monitoring subsequent growth. Invasion into the collagen 
indicates increased growth after injury. A microarray was performed to investigate 
relative changes in expression in a cut spheroid compared to an uninjured spheroid. 
Inflammation is recognized as being involved in cancer progression, and metastasis. 
Thus, a model studying a wound environment is of great interest due to widespread use of 
biopsies to diagnose malignant growth. In conclusion, we have demonstrated a method 
for mimicking a biopsy in an embedded spheroid model and preliminary results indicate 
that growth is increased after injury. 
 
Introduction 
The similarities between a growing tumors and a wound that does not heal was 
first outlined in 1986 by Dvorak, et al. 226. Since then, inflammation is understood 
 to contribute to cancer incidence, progression and metastasis 227. Chronic inflammation 
from environmental factors such as with asbestos and lung cancer or viral sources, as 
with human papilloma virus and cervical cancer is recognized as inducing a number of 
cancers 8. Inflammation has a larger role than inducing cancer, but also characterizes the 
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stroma which supports and maintains the tumor 146. Tumor progression from normal 
epithelial tissue to malignant tissue is characterized by the recruitment of inflammatory 
cells and presence of wound granulation tissue 7. Cellular components of the tumor 
stroma include fibroblasts, myofibroblasts, endothelia cells, pericytes, macrophages and 
notably a variety of inflammatory cells 170. Inflammation is further implicated in the self-
renewal of cancer stem cells which are associated with cancer recurrence, metastasis and 
chemoresistance. Cancer stem cells interact with inflammatory cytokines, which activates 
the NF-KB pathway, which has been shown to maintain a chronic inflammatory state in 
tumor cells. This leads to further cytokine production and positive feedback loops that 
govern CSC self-renewal 228. 
Based on the link between inflammation and cancer, inflammation is being 
explored as a prognostic factor for colorectal 229, lung 230 and gastroesophageal 231 cancer.  
Studies have sought to understand the downstream effects of treatments on inflammation. 
Treatment with chemotherapeutics can lead to elevation of inflammatory markers in 
breast cancer 232. However, even with the existing efforts aimed at understanding how 
inflammation and wound healing drive cancer progression, there is an absence of 
information on how mechanical injury could affect a tumor. Upon identifying a 
potentially malignant tissue, a biopsy is often performed to histologically diagnose the 
samples. In doing so, a wound is created within a potentially malignant tumor, where the 
downstream effects are not completely understood. Biopsies are widely used, with 62.6 
breast cancer biopsies performed per 10,00 women annually 233. Therefore, in this 
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manuscript we seek to establish a reproducible method for modeling an injury in a 
developing tumor.  
 
Materials and Methods 
Cell Culture 
CS-1 is a human sarcoma cell line that was cultured in Roswell Park Memorial Institute 
Media supplemented with fetal bovine serum (10%) and penicillin/streptomycin (1%, 
10,000 IU/mL penicillin; 10,000 mg/mL streptomycin). Cell lines were kept at 37 °C, in 
a humidified chamber with 5% CO2.  
 
Three Dimensional Cancer Models 
The method for spheroid formation and embedding in 4 mg/mL collagen followed a 
previously published method 185. After collagen was poured, it polymerized for one hour 
at 37 °C before 200 µl of media was added. 
 
Imaging 
DIC images were acquired on a DMI600B microscope (Leica, Solms, Germany) with an 
ImagEM EM-CCD Camera (Hamamatsu Photonics, Hamamatsu, Japan) in a spinning 
disc confocal setup (Yokogawa, Tokyo, Japan). Imaging was done using Micro-Manager 
1.4 Software (http://www.micro-manager.org). Assembling of frames into a single image 
was done in Matlab. 
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Spheroid Injury Model 
On the third day in collagen, media was removed from the spheroids. The injury was 
completed with a beveled needle without additional magnification. The spheroid and 
collagen were cut down the middle and then approximately half of the spheroid and 
collagen was removed. Any additional media left in the well was removed and then 
approximately 40–50 µl 4 mg/mL collagen was added into the space created. Media was 
added on top after a one hour incubation at 37°C. Growth was quantified by measuring 
invasion into collagen on the eighth day. Invasion into the collagen immediately after 
injury was considered baseline and subtracted from the total growth. Five measurements 
were taken per spheroid in ImageJ. 
 
DNA Concentration After Cutting 
DNA was purified from embedded spheroids using the mammalian tissue protocol from 
PureLink Genomic DNA Kits (Invitrogen, Carlsbad, United States) without any 
additional disaggregation. The DNA content was quantified with Quant-iTTM PicoGreen 
according to manufacturer instructions. Fluorescence was measured at ex/em 480/520 nm 
using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, United States) and 
converted to DNA concentration using a standard curve. 
 
Microarray 
RNA was purified from embedded spheroids using the Trizol Reagent (Invitrogen, 
Carlsbad, United States) monolayer protocol without additional purification. Multiple 
	  	  
112 
spheroids were pooled for a single sample. The Human Gene St 2.0 microarray with a 
total of 48,226 genes was run and analyzed by the Dana Farber Cancer Institute Core. 
 
Results 
Spheroids Growth After Injury 
We established a model for spheroid injury to mimic clinical biopsies. The injury was 
performed with a beveled needle, and images demonstrate that part of the spheroid was 
removed and replaced with collagen as shown in Figure 5.2A. After five days of 
additional culture, growth into the new collagen described as the “cut” half is apparent 
(Figure 5.2B). The growth into the collagen by the cut half and the “control” half of the 
spheroid left intact was measured. Figure 5.2C demonstrates that the cut half grew 
significantly farther into the collagen (p<0.01). 
 
Model Verification 
In order to measure the portion of spheroid that remained after injury and ensure that this 
method was reproducible, the DNA portion of the spheroid that remained after injury was 
assessed compared to an uncut spheroid. DNA concentration was used as a metric of cell 
number. The DNA concentration of a cut spheroid was 223 ng/mL compared to 470.4 
ng/mL for an uncut spheroid (Figure 5.3). Therefore after injury an average of 46.8 
±13.6% spheroid remained to grow into the collagen.  	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Microarray 
A Human Gene St 2.0 was performed with RNA from injured and control spheroids in 
order to look at genetic changes induced by injury. Out of a total of 48,226 genes, 1,086 
genes were classified as differentially expressed with a fold change greater than 2 or less 
than -2 and p<0.05. 381 genes were up-regulated and 705 genes were down regulated. A 
selection of the differentially expressed genes is shown in Figure 5.4. 
 
Discussion 
Due to interest in the effect of cancer treatments on subsequent inflammation, 
there exists a need for a cancer model that can mimic the response of a tumor to 
treatments as well as the induced inflammatory reactions. To this end, a multicellular 
collagen embedded spheroid will serve as a model of the developing tumor. Spheroids are 
multicellular aggregates formed to recapitulate tumor macrostructure started by 
Sutherland, et al. in the 1970s 19. Spheroids mimic the metabolic gradients found in a 
small tumor, with quiescent cells at the center and actively dividing cells at the periphery 
11. Collagen has been used to embed the spheroids as it provides a matrix for ingrowth as 
well as being a main component of the ECM 66. Importantly, spheroids have already been 
used as a model for a number of treatments such as chemotherapeutics 95, radiation 234, 
and nanoparticles 34. In addition, stromal components linked with inflammation have 
been incorporated into the spheroids such as tumor associated macrophages, cancer 
associated fibroblasts 27 and fibrin 119. Therefore, the embedded spheroid is an ideal 
model for measuring induced inflammation, as additional components can be added to 
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more accurately mimic the inflammatory process.  
 In this report, the method developed focuses on a model of mechanical injury in 
an embedded spheroid. The method involves cutting and removing part of a collagen 
embedded spheroid, and filling collagen into the newly created wound. This method is 
straightforward, and does not require additional instrumentation as shown in Figure 5.1. 
Imaging demonstrates that part of the spheroid is removed, and after additional culture, 
spheroid growth into the collagen is apparent (Figure 5.2). The method consistently 
removes approximately 50% of the spheroid (Figure 5.3). Preliminary results indicate 
that the injury promotes cancer growth as the cut side of the spheroids demonstrates 
increased growth when compared to the control half. Therefore, this is a useful model of 
mechanical injury resulting in partial removal of the spheroid, and growth after injury. 
To characterize the effect on a genetic level, RNA from cut spheroids was 
analyzed via a microarray. Of the 1086 genes found differentially expressed, only the 
most promising will be discussed for brevity (Figure 5.4). ALDH18A1 or Aldehyde 
dehydrogenase family 18 member A1 was upregulated 2.09 fold in the cut spheroids 
compared to the controls. Overexpression of the aldehyde dehydrogenase family has been 
correlated with an increase in cancer stem cells (CSCs) 210. Of the 19 isoforms of ALDH, 
ALDH18A1 has one of the five high mRNA expression, and responds to CSC agonist 
BMP 235. TGFβ1I1 TGF-β1 induced transcript 1 is upregulated 2.05 fold, and is a 
member of the Transforming Growth Factor β is a cytokine implicated in a number of 
processes such as growth and is notably upregulated in cancer. A gene array on clinical 
samples found TGFβ1I1 upregulated in metastatic versus primary ovarian serious 
	  	  
115 
papillomas 236. TNFRSF12A, a member of the tumor necrosis factor α (TNF-α) family is 
upregulated 2.48 fold has been identified as a potential biomarker in breast cancer and is 
linked to vascular cell migration and angiogenesis 237. The gene MCL-1 myeloid cell 
leukemia sequence-1 is upregulated 2.48 fold, and is an oncogene first discovered in 
leukemia that maintains viability and promotes differentiation 238. Based on preliminary 
analysis there are multiple genes of interest indicative of changes in expression induced 
by mechanical perturbation. 
 
Conclusion 
Therefore, in this report we demonstrate a novel method for inducing a 
mechanical wound in an embedded spheroid model of sarcoma to study downstream 
effects on cancer growth and progression. The method established is reproducible, facile, 
and free of additional instrumentation. Morphologically, increased growth occurs after 
injury suggesting growth promotion. Genetically, 1086 genes with altered expression 
have been identified for further study. Preliminary analysis noted genes associated with 
CSCs, viability maintenance, and growth. In conclusion, the novel method demonstrated 
could be used in conjunction with anti-inflammatory drugs to attempt to modulate post 
surgical inflammation. 
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Figure 5.1 The Biopsy Model:  
This model creates an injury in an embedded spheroid. A spheroid of CS-1 cells (red) is cut 
on the third day of culture. Approximately 50% of the spheroid and surrounding collagen 
(tan) are removed. Fresh collagen is filled into the vacant area, and growth is monitored 
over the next five days. 
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Figure 5.2 Spheroid Growth After Injury:  
A) The sarcoma spheroid is cut on the third day in collagen and new collaged is filled into 
the void. B) Images on the eighth day in collagen demonstrate growth into both the “cut” 
and “control” side of the spheroid. C) Invasion from day three to day eight was measured. 
Growth from the cut side was statistically higher (p<0.01) than the control side (n=4). 	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Figure 5.3 Method Validation:  
In order to confirm that the injury model was reproducible, the percentage of the spheroid 
was quantified by measuring DNA concentration of an injured spheroid. The average 
percentage cut was 46.8±13.6% with a range of 30–59% of the spheroid remaining (n=5). 	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Gene Fold Change 
TGFB1I1 2.05 
ALDH18A1 2.09 
TNFRSF12A 
2.48 
MCL1 2.48 
Figure 5.4 Genetic Changes After Mechanical Injury: 
In order to understand the downstream effects of mechanical perturbation on an embedded 
spheroid model, a microarray was used to look at changes in expression. Of the 1,086 genes 
that demonstrated a change in expression, these four are linked with differentiation, growth 
and cancer stem cells. 
.
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Designed and executed experiments for prototype validation 
 
Bioactive Surgicals Baltimore, MD  
Lab Technician Fall 2008 – Spring 2010 
 Made key decisions concerning product design and fabrication  
Designed and executed experiments for product validation 
Contributed to grant writing and editing  
 
Northwestern University Chicago, IL 
Research Experience for Undergraduates Summer 2009 
Assisted in fabrication and testing of an organic solar cell 
Exposed to scanning and transmission electron microscopy and synthesis 
 
Monell Chemical Senses Center Philadelphia, PA 
Monell Science Apprenticeship Program Summer 2008 
Performed vector design for further work with taste receptors 
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Memorial Sloan-Kettering Cancer Center New York, NY 
Summer Undergraduate Research Program Summer 2007 
Performed experiments to characterize a putative oncogene 
 
Mount Sinai School of Medicine New York, NY 
 High School Student Volunteer  Summer 2004, 2005 
 Performed experiments to characterize a putative oncogene 
 
Awards:  
First Place Team JHU BME Design Day (2009) 
Third Place Team JHU Business Plan Competition in Biotechnology (2009)  
Intel Science Talent Search Semifinalist (2006) 
Fourth Place in Biochemistry at Intel International Science and Engineering Fair (2006) 
Won the Weizmann Award to do research at the Weizmann Institute in Rehovot, Israel 
(2006) 
Won first Place in Biochemistry at NY State Science and Engineering Fair (2006) 
Awarded as an Intel Science Talent Search Semifinalist (2006) 
 
Publications: 
1. Annaluru, N.; Muller, H. l. Ø.; Mitchell, L. A.; Ramalingam, S.; Stracquadanio, G.; 
Richardson, S. M.; Dymond, J. S.; Kuang, Z.; Scheifele, L. Z.; Cooper, E. M., Total 
Synthesis of a Functional Designer Eukaryotic Chromosome. Science 2014, 344 (6179), 
55–58. 
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2. Ghobril, C.; Charoen, K.; Rodriguez, E. K.; Nazarian, A.; Grinstaff, M. W., A 
Dendritic Thioester Hydrogel Based on Thiol-Thioester Exchange as a Dissolvable 
Sealant System for Wound Closure. Angewandte Chemie International Edition 2013, 52 
(52), 14070–14074. 
3. Charoen, K. M.; Fallica, B.; Colson, Y. L.; Zaman, M. H.; Grinstaff, M. W., 
Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug 
and drug-device combinations. Biomaterials 2014, 35 (7), 2264–2271. 
4. Lei, H., Hofferberth, S. C., Liu, R., Colby, A., Tevis, K. M., Catalano, P, et al. 
Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in 
mesothelioma 3-dimensional multicellular spheroids. The Journal of thoracic and 
cardiovascular surgery. 2015 149(5), 1417–1425. 
5. Tevis, K. M., Cecchi, R., Colson, Y. L., & Grinstaff, M. W. An in vitro model of 
tumor associated macrophage interaction with malignant cells in an embedded spheroid. 
In preparation. 
 
Oral Presentations: 
1. Charoen KM, Fallica B, Zaman M, and MW Grinstaff.  “Efficacy of Nanoparticle 
Drug Delivery System in an Embedded Spheroid Tumor Model.” Materials Research 
Society Fall Meeting & Exhibition – Boston, MA, December 1 – 6, 2013.  
2. Tevis KM, Reynolds D, Zaman M, and MW Grinstaff.  “Efficacy of Paclitaxel 
Impacted by Both Three Dimensional Culture and Tumor Macrostructure.” Materials 
Research Society Fall Meeting & Exhibition – Boston, MA, November 29–December 4, 
2015 
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Posters: 
1. Charoen KM, Yohe ST, Grinstaff MW. Electrospun Janus Meshes. Poster session 
presented at: National Institute of Biomedical and Bioengineering 2012 Training 
Grantees Meeting; June 28–29; Bethesda, MD. 
2. Charoen KM, Yohe ST, Grinstaff MW. Controlled Deposition of Electrospun Fibers 
for Bilayer and Janus Meshes for Biomedical Applications. Poster session presented at: 
2012 Materials Research Society Fall Meeting; Nov. 25–30; Boston, MA. 
3. Charoen KM, Stolzoff M, Grinstaff MW. Polymeric Nanoparticles Obtained from 
Beaded Electrospun Meshes. Poster session presented at: ASME 2013 2nd Global 
Congress on Nanoengineering for Medicine and Biology; Feb. 4–6, Boston, MA. 
4. Charoen KM, Konry T, Cohen S, Avigan D, Yarmush M, Grinstaff MW. 
Transplantable Matrix Permits T Cell and Dendritic-Fusion Cell Interaction. Poster 
Session Presented at: Society for Biomaterials 2013 Annual Meeting & Exposition; April 
10–13; Boston, MA. 
5. Charoen, K. M., Zaman, M., & Grinstaff, M. W. The Effect of Stromal Elements on 
Spheroid Response to Drug Delivery. Poster session presented at: the meeting of Cancer 
Nanotechnology Gordon Research; July 2013; Conference, West Dover, VT 
6. Cecchi, R. J., Charoen, K. M., & Grinstaff, M. W. A Solid Tumor Model with 
Opportunities for Studying Immune Component Interactions. Poster session presented at: 
The 2014 meeting of Materials Research Society Fall Meeting & Exhibition; November 
30–December 5; Boston, MA. 
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Skills: 
- Mammalian cell culture techniques including cell line propagation, working with frozen 
stocks, and harvesting cells for further analysis 
- Subcloning techniques such as transformation, PCR, site directed mutagenesis and 
vector design (ligation and restriction enzyme reactions) 
- Immunofluorescence, Elisa assays, and Luciferase assays 
- Trained in confocal and scanning electron microscopy 
- Electrospinning and polymer preparation 
